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Chapter 1
Introduction
Protein misfolding has long been known to constitute an important class of disease ini-
tiating factors. Of special significance in this group is Alzheimers disease (AD) in which
the aggregation of misfolded small molecular weight amyloid β peptides (Aβ) triggers a
host of biochemical anomalies that destroy brain neuronal processes. AD is recognised
as the most common form of dementia in the elderlies and characterised by a progressive
loss of brain neural and synaptic functions. While a number of cellular processes have
been implicated in AD, the overwhelming majority of research evidences support Aβ as
being central in Alzheimer’s pathogenesis. Alzheimer’s disease was first described by the
German neuropathologist, Alois Alzheimers in 1906. However, in spite of the enormous
efforts invested into AD research over the past century, there still remain crucial questions
that are yet to be answered, in particular with respect to AD treatment. In other words,
after 100 years of research, AD remains incurable. Even though a number of drugs exists
for the relief of associated symptoms, there is at the moment no definitive treatment that
halts the progressive neurological decline in AD patients. An explanation for this may be
found in the peculiarities of the Aβ peptide, the molecular target commonly targeted for
drug development.
Aβ is produced via post-translational cleavage of the transmembrane amyloid precur-
9
Introduction
sor protein (APP) followed by its release into the extracellular medium. Unlike most
other protein drug targets however, Aβ both lacks a regular three dimensional fold and
possesses a significantly high aggregation propensity under physiological conditions. In
healthy individuals, the production of Aβ is delicately balanced by its clearance, and when
this balance is thrown out of sync, as observed in AD, aggregating Aβ initiates the neu-
ronal and synaptic damage charactising AD. However, Aβ’s extremely high aggregation
tendency renders most available experimental structure determination tools to an extent
unable to determine its physiologically relevant conformations. Attempts to address this
challenge includes the use of nonphysiological solubilising conditions, which at the same
time compromises the usefulness of such models for Aβ-directed drug discovery. This,
however, is just one of the several dimensions of the challenge associated with the Aβ
peptide.
Also unlike most drug targets, the Aβ peptide exhibits a high level of structural hetero-
geneity involving different truncated forms of the 39 to 43-residue Aβ monomer, each
exhibiting unique structural and toxicity properties. Added to this, Aβ monomer ag-
gregates into differently sized, conformationally and toxicologically diverse oligomers and
fibrils. In other words, the number of structural states that Aβ can adopt is so immense
that it constitutes a potent challenge to therapy development. It is therefore obvious
that the search for definitive treatment of AD will significantly benefit from an in-depth
understanding of Aβ’s structural dynamics. This will necessarily depend on first finding
a means of studying Aβ conformations under physiological conditions. In this work, we
have employed a number of molecular simulation approaches to address these challenges.
We study and describe the structural dynamics of the two physiologically dominant Aβ
species–Aβ40 and Aβ42 monomers.
Using multiple molecular dynamics (MD) simulations on microsecond time scale, we stud-
ied the conformations of Aβ40 and Aβ42 in explicit water and under simulation conditions
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mimicing physiological conditions. To validate the obtained results, we employed chemical
shift calculations which we compared with Nuclear Magnetic Resonance (NMR) chemical
shifts, enabling us identify the force field that correctly models experimentally relevant
Aβ structural ensembles. An explanation is advanced for the differences observed in force
fields, especially with respect to natively disordered peptides of which Aβ is a type. We
provide an atomistic explanation for certain important aspects of the Aβ structure, such
as the observed differences between Aβ40 and Aβ42 monomers, and the intramolecular
factors that drive conformational behaviour of Aβ under different pH conditions.
Our goal for analysing Aβ’s conformation is to obtain structural ensembles closely resem-
bling the physiological state, for use in investigating Aβ’s interaction with aggregation
inhibitors currently investigated in the group of Prof. Dr. Willbold (ICS-6 Forschungszen-
trum, Ju¨lich). These aggregation inhibitors were discovered using the mirror image phage
display technique. They showed promising anti-amyloid activities against Aβ42 in in vitro
tests and improved behaviour indices in transgenic mice. The inhibitors abolished Aβ’s
toxicity in a dose-dependent manner, but their mechanism(s) of action, to a large extent,
remains unknown. The aim of our study is thus to provide explanation for the mode
of action for the observed anti-amyloid effects of the D-peptide inhibitors. Our in sil-
ico investigation is based on an hypothesis linking Aβ’s neurotoxicity to its structure,
in particular the β-sheet content. The evidence for this came from an observation that
the D-peptide- treated solutions of Aβ lose their toxicity to cultured cell and at the same
time their β-sheet contents. The structural effects obtained in our calculations thus serve,
both as a means of approximating and comparing the D-peptides’ anti-amyloid effects,
as well as provide a way of validating the correctness of our results with respect to ex-
perimental observation. Our calculations reveal the possible mechanism of action of the
D-peptides, and at the same time provide a detailed description of their effects on Aβ’s
secondary structure. We also performed exhaustive point mutations on the D-peptides’
11
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sequences using both natural amino acids and some non-standard residues. The results
suggest possible modifications that can be performed on the original D-peptides’ amino
acid sequences that can help modify their selectivity for different Aβ oligomer sizes.
12
Chapter 2
Molecular dynamics
2.1 Introduction
”Given for one instant an intelligence which could comprehend all the forces
by which nature is animated and the respective situation of the beings who
compose it–an intelligence sufficiently vast to submit this data to analysis–
it would embrace in the same formula the movements of the greatest bodies
of the universe and those of the lightest atom; for it, nothing would be
uncertain and the future, as the past, would be present in its eyes.”[1]
–Pierre-Simon Laplace writing on causal determinism (1812-1820)
Dynamics simply put describes the motion and at the same time the property of a particle
or system of particles undergoing motion, which in biological systems represents an insepa-
rable aspect of biomolecular processes. Fairly recently the study of the dynamic properties
of biological systems from different perspectives (chemist, biologist and physicist’s) have
assumed significant proportion, and that not unnecessarily given the critical roles played
by dynamic processes in living systems. The microscopic scale characterising most bi-
ological processes in some cases has caused biomolecular dynamics to elude reckoning.
For instance, biomolecular processes had for some time been approached as involving still
13
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molecules (an example is the lock-and-key model used to describe the interaction of drug
molecules to their biological receptors). The realisation that a description of biochemical
functions remains incomplete without accounting for structural dynamics of constituent
particles (e.g., atoms and molecules) is a major driving factor spurring the rapid growth
in the study of molecular scale dynamics. Added to this are a plethora of powerful ex-
perimental tools such as X-ray crystallography, nuclear magnetic resonance, atomic force
microscopy, circular dichroism (CD), electron microscopy and fluorescence assays used
in biomolecular structure determination and limited aspects of structure dynamics, for
instance, using solution Nuclear Magnetic Resonance (NMR) techniques. Molecular scale
motions, however, traverse such broad time and distance scales (table 2.1) typically rang-
ing from the fast femtosecond-scale vibrational motions featuring small amplitudes (≈
0.01 A˚) and energetics (≈ 0.1 kcal/mol) to the much slower domain and global rearrange-
ments occurring on hour scale characterised by much larger amplitudes (≈ 100 A˚) and
energies (≈ 100 kcal/mol)[2]. Within the two extremes lie a host of intermediate scales
each of which has specific biological relevance. These different scales do not exist in isola-
tion relative to one another, instead they are interdependent–coupled– in that the smaller
scale motions determine the dynamics of processes existing on larger scales in such a way
that the largest dynamics (both distance- and time-wise) is indirectly dictated by the
smallest motion [2].
The dynamic properties of biomolecular systems are often inseparable from biological
Molecular motion Typical time-scale (s) Amplitude (A˚) Accessibility
Bond vibrations 10−15 − 10−12 < 1 Fully
Loop motions 10−9 − 10−6 1-5 Fully
Domain movement 10−6 − 10−3 5-10 Fully
Protein folding and interaction 10−3 − 104 >10 Partly
Table 2.1: Time-scales of biological systems[2].
functions; however, such motions usually occur on scales that put them beyond the scope
of many conventional experimental techniques. Fortunately many of these biologically
relevant dynamics happen on time-scales that have become amenable to molecular scale
14
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simulation methods, such as deterministic methods making use of empirical potentials
in which either the Newtonian or the Lagrangian equation of motion is integrated over
time to obtain the positions and momemta of particles (idealised atoms) of the system
of interest[3]. Added to the recent tremendous progress in computer ware and algorithm
development, the investigation of biomolecular dynamic processes have increasingly been
brought within the domain of computational methods, thus providing a powerful and in-
creasingly indispensable high resolution details to complement experimental investigation.
2.2 The molecular dynamics algorithm
A molecular dynamics simulation involves solving the Newton’s second-order equation of
motion for atom i having mass mi experiencing a net force Fi and typically within a
system featuring other interacting particles.
Fi = miai (2.1)
= mir¨i (2.2)
= mi
∂2ri
∂t2
(2.3)
Although the specific implementation of the code varies with parameterisation philosophy,
the fundamental sequence of steps comprising an MD algorithm include: 1) the specifica-
tion of the initial conditions, 2) the calculation of atomic forces, 3) configuration update
involving the integration of the equation of motion, and 4) data (i.e., output) collection
and analysis [4].
15
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2.2.1 Initial set of conditions–positions and velocities
The molecular dynamics algorithm is a deterministic simulation method. Deterministic
in the sense that starting with a specified set of initial system conditions, the method
can be used to provide exact solutions for state properties such as positions and velocities
(i.e., the phase space) at later time-points[5]. An MD simulation typically commences
with the specification of the starting coordinates R(t = 0) at time zero, consisting of
coordinates r1,2,3...,N for N atoms. The degrees of freedom represent the 6N -dimensional
phase space corresponding to the x, y and z components of the positional vectors ri and
the momentum vectors pi for each atom i. When completely specified for all atoms, the
phase space vectors R and P represent together a microstate in the phase space[6].
With ri known, a value for the initial interaction U(t = 0) (with velocities known) and
the initial velocities v1,2,3...N (may be optional in some MD codes; with U(t = 0) known)
of the N atoms can be calculated [4]. The starting coordinates, R(t = 0), for all atoms
are usually obtained from experimental techniques such as X-ray crystallography and
NMR, and in some cases from homology modelling[2]. Often times however, the initial
structures require some pretreatment and structural refinement before they are suitable
for use in molecular dynamics simulation. Hydrogen atoms, for instance, being too light
for X-ray scattering often have their coordinates missing in X-ray structures; while the
high structural flexibility characterising residues (both protein and nucleic acids) in loop
segments hamper their determination by both NMR and crystallographic methods. In
certain instances also, the missing residues result from deliberate removal as part of the
X-ray crystallographic procedure. Fortunately however, a number of computational tech-
niques exist to preprocess such starting coordinates and add in the missing atoms and
residues even up to whole absent loop regions.
Once the starting atomic positions have been fully specified there arises next the need to
specify the initial velocities which in most cases can not be obtained empirically. With
16
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the system temperature specified (typically but not always 300 K), however, the initial
velocities may be assigned according to a Maxwellian distribution, conducted initially in
an ad hoc manner,
P (v) =
√
m
2pikT
e
(
−mv2
2kT
)
(2.4)
where P (v) is the probability, m and v are respectively the atomic mass and velocity,
while k is the Boltzmann constant. The initial system setup is however sometimes far
from equilibrium partly resulting from the random manner in which velocities were as-
signed. This may also result from factors associated with the specific details of the method
employed in generating the starting set of coordinates. For this reason further fine-tuning
of the assigned velocities may be necessary. Starting with low temperature values where
the system atoms feature wildly fluctuating kinetic energies (and thus velocities, equation
(2.5)),[2] the temperature is slowly increased (in principle) until thermal equilibrium is
achieved. From the equipartition theorem (equation (2.6)), it is possible to compute the
system average kinetic energy and thus the velocities. The new velocities corresponding
to thermal equilibrium can then be assigned. A second workaround involves iteratively
assigning the velocities from the Maxwellian distribution until certain predefined conver-
gence criteria are met.
The equipartition theorem allows to connect the system temperature T with the atomic
velocities vi:
Ekin =
1
2
mv2 (2.5)
T =
(
1
k3N
) N∑
i=1
∑
a=x,y,z
miv
2
i,a (2.6)
where vi,a refers to the velocity of atom i in either x, y or z direction.
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2.2.2 Computing forces between interacting atoms
The level of detail being modelled will necessarily affect the manner in which the force
calculation is conducted. This as well affects how atomic positions and momenta are sub-
sequently computed. [3] For systems for which less-than-atomic resolution is acceptable
some other equations of motion are solved to obtain forces: for instance the Lagrangian
equation employed for studying whole domain motion, while solution of the Langevin
equation is more appropriate for stochastic processes [3] In systems requiring atomistic
detail description, numerical solutions of Newton’s equation of motion are required for
every atom and in each x, y and z direction. Solution to the Newtonian equation for
atom i in equations (2.1) to (2.3) yields the atomic coordinates ri at time t. In order to
obtain the atomic forces, from which positions and momenta are subsequently computed,
the gradient of the atomic potential, −∇iU, is taken with respect to the position vector
of atom i:
Fi = −∇iU (2.7)
= −∂U(R)
∂ri
(2.8)
That is, forces are only computed from the interaction part of the Hamiltonian H which
is equivalent to the total energy and comprises the kinetic energy which is a function of
the atomic momenta (pi = mir˙i), as well as the potential (interaction) energy part which
is a function of the atomic coordinate ri:
H(P,R) = Ekin(P) + U(R) (2.9)
=
∑
i
(
1
2
)
mir˙
2
i (p) + U(r) (2.10)
18
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2.2.3 Integrating Newton’s equation of motion
An MD simulation involves sampling the phase space by tracking the time-dependent
evolution of the system via time discretisation and choice of an appropriate time-step to
integrate the equation of motion. The molecular dynamics simulation of biomolecular
systems studied in this work is based on the numerical solution of Newton’s second law of
motion for a system of interacting particles. Knowing the system coordinates, velocities
and forces at time t, the task is thus to calculate subsequent positions of the interacting
atoms following a step taken in time space. The resulting sequence of positions as a func-
tion of time are referred to as a trajectory. In principle, what is done is to calculate the
atomic forces, using a force field described in 1.3.3, from which the subsequent velocities
and positions can be obtained.
Molecular dynamics employs the finite-difference method for the numerical solution of the
equation of motion[2]. To this end, the time space is discretized,
τ = t0 + n
∑
∆t (2.11)
where τ is the length of the simulation, t0 is the initial time (often zero), ∆t is the
time-step, and n is the number of such steps taken during the simulation. In the finite-
difference method, the atomic velocities and positions after taking a ∆t time-step (i.e.,
at tnew = t + ∆t) are calculated using the corresponding values before the time-step. In
practice, however, this is only possible when the value chosen for ∆t is sufficiently small
(usually between 1–2 fs) in order to capture the fastest motion of the system, which is hy-
drogen bond vibration (table 2.1). Otherwise, the magnitude of accumulated error would
become too large.
Three popular integration algorithms exist: the Verlet algorithm, the Leap-frog algorithm
and the Velocity-Verlet algorithms with the last being the most accurate especially with
19
Molecular dynamics 2.2 The molecular dynamics algorithm
respect to velocity calculation, and the first being the least. They are all based on Taylor
expansion of the atomic positions:
r(t+ ∆t) = r(t) + v(t)∆t+
(
1
2m
)
F(t)∆t2 + . . . (2.12)
The equation calculates the new coordinate at (t+∆t) from the current coordinates (first
term on the RHS), the current velocities (second term on the RHS), the current accel-
eration (third term on the RHS) and higher order terms. In practice the higher orders
are usually ignored while evaluating the expansion. The Verlet algorithm is based on
two such Taylor expansions, one for the future (t + ∆t, equation (2.13)) and one for the
past (t − ∆t, equation (2.14)). By summing up the two expansions all terms with odd
numbered orders (∆t1, ∆t3, ∆t5 . . . ) cancel out, and the coordinates at t+ ∆t can then
be calculated from the current coordinates and forces, and the previous coordinates[2]:
r(t+ ∆t) = r(t) + v(t)∆t+
(
1
2m
)
F(t)∆t2 +O(∆t3) (2.13)
r(t−∆t) = r(t)− v(t)∆t+
(
1
2m
)
F(t)∆t2 −O(∆t3) (2.14)
r(t+ ∆t) = 2r(t)− r(t−∆t) + F(t)
m
∆t2 +O(∆t4) (2.15)
v(t) =
r(t+ ∆t)− r(t−∆t)
2∆t
+O(∆t2) (2.16)
When equations (2.13) and (2.14) are substracted the value of the velocity is obtained
(equation (2.16)). The main advantages of the Verlet algorithm are its associated low
computational cost deriving mostly from the use of single force calculations per time-step
and its time-reversibility [2]. The disadvantages associated with the algorithm includes
the fact that velocities at t can only be calculated when the positions (r(t + ∆t)) are
known. Another disadvantage is the integration error for velocities being in the order of
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O(∆t2). This, however, has been reduced by the more recent modifications to the Verlet
algorithm, such as the Leap-frog algorithm, which evaluates velocities at half time-steps,
and the Velocity-Verlet algorithms. A detailed description of the two algorithms can be
found in reference [2].
2.2.4 Data analysis
The classical equation of motion as described above is solved at every time-step for the de-
sired length of simulation (τ), yielding a trajectory. The coordinates, velocities, potential
energy, pressure, etc can then be used to compute the desired time-averaged equilibrium
properties [7]. Examples include the root-mean-squared deviation (RMSD) which can ei-
ther be averaged over selected coordinates to temporally trace the structural fluctuation,
or over time in which case the relative fluctuation of the different subsets (e.g., a loop
region) of the system can be determined. Generally, analysis of MD-generated trajectories
typically involves calculating the time average of a desired quantity A over the length of
the simulation T :
〈A(r,p)〉time = lim
T→∞
1
T
∫ T
t=0
A(r(t),p(t)) dt (2.17)
In order words, 〈A(r,p)〉time represents the average, which is a function of the position
r and momentum p, calculated for a single point over the several time steps making
up the total simulation time. MD-derived average contrasts with what obtains at the
macroscopic level, where an ensemble average (equation (2.18)) represents several multi-
ple points existing at the same time:
〈A(r,p)〉ensemble =
∫∫
A(r,p) ρ(r,p) dr dp (2.18)
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where ρ(r,p) is the probability density. According to the ergodic hypothesis [8], at
the limit of an infinitely long MD trajectory, 〈A(r,p)〉time converges to 〈A(r,p)〉ensemble.
Rather than conducting infinite MD sampling, in practice, what is done is to generate
trajectories that are long enough for the simulated system to have equilibrated. Sub-
sequent trajectory analysis then involves calculating the time averages of the desired
quantities (〈A(r,p)〉time) and approximating these as representing the ensemble average
(〈A(r,p)〉ensemble). To a large extent the validity of this assumption will depend on the
degree to which the phase space has been sampled. And generally, the longer the simu-
lation the larger the part of sampled phase space. There are different types of properties
that can be calculated from an MD trajectory, but the analyses eventually performed will
depend on the question the simulation seeks to address. The properties calculated in the
present work are discussed in the relevant sections.
2.3 The potential energy function
The potential energy function represents a set of mathematical expressions that allow
a atomic system’s potential energy to be obtained from its 3-dimensional structure [2].
The mathematical models employed efficiently capture the various physicochemical inter-
actions contained in the system[2]. Such potential energy functions are often typically
designed for a defined group of molecular systems such as proteins, and are commonly
referred to as force field. Individual force fields are developed with various objectives in
mind, but practical applicability often demands that the employed forms of the mathemat-
ical expressions aim at achieving a balance between accuracy, implementation efficiency
and practical applicability [2]. It can as well be argued that the emergence of force field
methods already represents a major compromise between model accuracy and applica-
bility compared with quantum mechanical approaches in which electrons are explicitly
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treated. The advantage of accuracy obtainable in quantum mechanical (QM) treatments
is, however, at the same time a major limitation to their relevance in investigating most
biomolecular systems of interest. This is mostly because the high-level quantum chem-
ical calculations employed in QM treatment are in reality only able to study systems
containing less than 100 atoms and quickly requiring beyond available computational re-
sources for larger systems. Nonetheless, force field development has immensely benefited
from quantum mechanics for the derivation of force field parameters. Furthermore the
Born-Oppenheimer approximation which decouples the nuclear and the electronic wave-
functions serves as an important foundation for the classical treatment employed in force
field methods.
The potential energy, written as U(R) in equation (2.8) specifies the interaction energies
between the atoms composing the system but can also includes contributions to the en-
ergy function resulting from the use of special restraining forces during an MD protocol.
An instance is the use of restraints in biasing defined inter-atomic distances or angles[9].
These special interactions must then be accounted for as part of the potential energy
while computing forces.
The mathematical description of the potential energy function comprises two core ingre-
dients: bonding terms which specify the energy contributed by covalent bond terms, and
the nonbonding terms specifying contributions between atoms that are not via covalent
connections:
U = Ub + Unb (2.19)
where both Ub and Unb are in turn composed of separate terms the specific details of which
depend on the adopted functional form.
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2.3.1 Bonded interactions
The Ub term is obtained as a sum over all covalent bond lengths, bond angles, bond
torsions (or proper dihedral angles, often called dihedrals for short), and an improper
dihedral term:
Ub = UBonds + UAngles + UTorsions + UImproper (2.20)
Based on Fig. 2.1 an example for each of these four contributions is given:
• The covalent bond formed between atoms i and j: e.g., the C—CA bond
• The bond angle formed by atoms i, j and k and centred around j: e.g., the
C–CA–N angle
• The torsional angle involving successive atoms i, j, k, l: e.g., the angle defined
around the bond CA—N between the two planes (shown as gray triangles) involving
atoms C, CA, N and atoms CA, N, H.
• The improper dihedral involving four atoms i, j, k, l where j, k, l are all directly
bound to i. The improper torsion is also known as the out-of-plane bending term. It
is especially useful in cases where it is necessary to enforce a particular configuration,
such as planarity or chirality and tetrahedal centres[9]. In figure 2.1 the planarity
of the ring is enforced by an improper dihedral angle defined as the angle between
the planes spanned by Cb, CD1, CD2 and Cb, CG, CD1
The separate bonded terms are often treated either as harmonic or trigonometric func-
tions. For the harmonic treatment, the bond length, bond angle and improper dihe-
dral terms are calculated respectively as sum over the total number of covalent bonds
(ib = 1, 2, 3, . . . , Nb), bond angles (iθ = 1, 2, 3, . . . , Nθ), and improper dihedral angles
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Figure 2.1: Phenylalanine for the illustration of bonded interactions.
(iω = 1, 2, 3, . . . , Nω) according to the Hookean spring equation:
Uα =
Nα∑
iα=1
1
2
Kα[α− αeq]2 (2.21)
where α is any of b, θ and ω, and Kα represents the harmonic force constant for the motion
in question, and αeq is the equilibrium value of the bond or (improper dihedral) angle.
The force constants, usually obtained from spectroscopic measurements of related com-
pounds or from QM calculations, [2, 9] are typically defined for specific types of bonded
interactions. These are then supplied as parameters in the mathematical formulation of
the potential function. As an illustration, the value of Kb for a C-sp
3—C-sp3 (σ-bond)
bond is expected to be different from the value for either of a C-sp2—C-sp2 (pi-bond) or a
C-sp3—N-sp3 bond. The equibrium value αeq is, like the force constant, supplied as input
parameter for different bond types (e.g., C-sp3—C-sp3 versus C-sp2—C-sp2), bond angle
types (e.g. a tetragonal centred around sp3-C versus a trigonal centred around sp2-C),
and improper angles. In addition, the equilibrium values for both bonds and angles (αeq)
can also be obtained from experimental measurements (X-ray diffracton in particular)[9]
and QM calculations.
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An harmonic function is generally sufficient in capturing the properties of covalent connec-
tions which generally oscillate around the equilibrium values under commonly encountered
conditions. It is however important to note that the adopted functional forms of each of
these models also crucially depend on the need to simplify and reduce the number of
computational operations that need to be evaluated while computing the potential. For
instance, the new generation GROMOS force fields employ a non-harmonic function for
the bonds:
Ub =
Nb∑
ib=1
1
4
Kb,anharm[b
2 − b2eq]2 (2.22)
This form allows a reduction in the number of mathematical operations requiring square
roots evaluation and by so doing simplifies the calculations. Similarly, a cosine expression
is employed (GROMOS) for the bond angles (equation (2.23)), evaluating cos θ rather
than θ, which reportedly improves numerical stability and allows the operations to be
performed more efficiently [9].
Uθ =
Nθ∑
iθ=1
1
2
Kθ[cos θ − cos θeq]2 (2.23)
In the case of the torsion angle a different function capable of adequately capturing the
unique features of the angle is required. For these, the cosine function is used either
in a Fourier expansion (equation (2.24)) or Ryckaert-Bellemans formulation (equation
2.25) which more satisfactorily (compared with an harmonic function) models the periodic
nature of a torsion angle moving through angles ranging from 0◦–360◦ (or -180◦ depending
on adopted the angular definition):
Uφ =
Nφ∑
iφ=1
∑
m=1
Kφ,m[1 + cos(mφ− δ] (2.24)
Uφ,RB =
Nφ∑
iφ=1
5∑
m=0
Cm[cos(φ− 180◦)]m (2.25)
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The cosine function, in addition, better models the uniquely small energy barriers that
exist between multiple stable states, which partly result from the influence of nonbonded
interactions on the torsional potential [4, 11]. As a result of the dependence of the tor-
sional potential on the nonbonded interaction, the Ryckaert-Bellemans function ignores
the through-space interaction between the two outer atoms (i.e, 1-4 interaction) during
nonbonded interaction calculation while in the implementation in GROMACS, for in-
stance, special dispersion parameters are employed for the two atoms.
2.3.2 Nonbonded interactions
The nonbonded component of the interactions involve pairwise interactions transmitted
via space and not via the covalent network of bonds and angles[10]. There are two types
commonly included in most force fields: the electrostatic interaction resulting from ex-
plicit charges (e.g., attraction potential between oppositely charged aspartate and lysine
sidechains) and the van der Waals contribution (vdW, dispersion) resulting from uneven
and instantaneous electron distribution:
Unb = UvdW + UElectrostatic (2.26)
In the calculation of nonbonded interactions covalently bonded atoms are generally ex-
cluded. This may take the form of an exclusion list of all atoms connected via 1 or 2
bonds for which nonbonded calculations are not performed.
Compared with the electrostatic interaction (attractive and repulsive) which is a long-
range interaction as it scales with 1
r
where r is the distance between the interacting
atoms, the vdW interaction is a short-range interaction. The van der Waals potential
becomes attractive as the interaction distance decreases to an intermediate value, result-
ing from an electron redistribution also known as induced dipoles. On further decreasing
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the distance, electron clouds from different atoms get too close and the potential turns
repulsive[11]. This unique distance-dependent behaviour can be conceived of as arising
from the electrons getting in each other’s way [12] at distances smaller than the sum
of the interacting atomic radii where the interaction is dominated by high nuclear and
electron repulsion. The employed functional forms thus seek to adequately capture three
core aspects of the potential. That is: repulsive at short distances, slightly attractive at
intermediate distances, and vanishing at large distances. The different forms employed
usually only differ in the repulsive component. While the Buckingham [13] and the Morse
potentials [14] yield better results, the Lennard-Jones (LJ) potential is more commonly
preferred because of its associated lower computational cost:
UvdW = Uij − Cij
r6ij
(2.27)
UBuckingham = Aij exp
Bijrij −Cij
r6ij
(2.28)
UMorse = Dij
[
1− exp
(
−
√
k
2Dij
rij
)]
(2.29)
ULJ = 4ij
[(
σij
rij
)12
−
(
σij
rij
)6]
(2.30)
where Cij(vdW ) 6= Cij(Buckingham). Equation (2.27) captures the essential ingredients
for modelling van der Waals interactions. The choice of exponential functions by the
Buckingham (2.28) and Morse (2.29) functional forms more accurately capture the dis-
tance dependence than the LJ function (2.30). The constants Aij, Bij, Cij, and Dij, are
parameters defining the interaction of atoms i and j. The repulsive part defined in the
Lennard-Jones formulation by Aij/r
12
ij is chosen for no obscured reasons than to ensure
that it vanishes faster than the attractive part (dispersion) as rij increases [11]. The
choice of 12 for the exponent is thus mainly for the ease of computation (r12ij = (r
6
ij)
2)
for which reason other force fields can be found using values other than 12. Aij and Bij
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are values depending on the atomic radii of the atoms involved in interaction and are
supplied as parameters for the particular atom types [9] being treated. Equation (2.30)
shows the functional form of the LJ potential employed by MD codes like GROMACS.
The parameter σij is the value of rij at the minimum energy while ij is the depth of the
potential minimum energy.
The electrostatic interaction of charged groups (atoms and group of atoms) within the
system is usually modelled by the Coulombic function where partial charges are assigned
to the concerned atoms:
UCoul. =
1
4piε0
qiqj
εrrij
(2.31)
where qi and qj are respectively the partial charges of atoms i and j, while εr and ε0 are
respectively the relative dielectric constant and a distance dependence of the εr included
to include the screening effect of the medium. While functions including polarisation
effects and higher multipoles have proved more accurate at modelling the electrostatic
potential, such functions often come with high computation cost which has continued to
make the Coulombic model an attractive choice. For instance, evaluation of all pairwise
electrostatic interactions is associated with a O(N2) complexity. In practice, schemes
using spherical cutoffs such as the switching and shifting functions to a significant degree
reduce the discontinuity in energies and forces resulting from the use of simple trun-
cation, and have been used extensively in computing nonbonded interactions. A better
treatment of the long-range component of the electrostatic interaction in biomoecular sim-
ulation is achieved with the particle-mesh Ewald method (PME), an Ewald sum methods
which computes electrostatic interaction using a lattice with periodic boundary conditions
(PBC). With the PME the evaluation complexity is reduced to O(N logN).
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The overall potential energy function for the system can therefore be written in the form,
U =
Nb∑
ib=1
1
2
Kb[b− beq]2 +
Nθ∑
iθ=1
1
2
Kθ[θ − θeq]2
+
Nφ∑
iφ=1
∑
m=1
Kφ,m[1 + cos(mφ− δ] +
Nω∑
iω=1
1
2
Kω[ω − ωeq]2
+
N∑
i<j
4ij
[(
σij
rij
)12
−
(
σij
rij
)6]
+
N∑
i<j
[
1
4piε0
qiqj
εrrij
]
(2.32)
The discussion of the implementation details and the specific mathetical treatment em-
ployed by different force fields and MD codes is beyond the scope of this thesis, which
aims at providing an overview, though incomplete but sufficiently broad to highlight the
most important contributory terms typically employed in a force field.
The actual force calculation is performed by taking the first derivative of the calculated
potential energy with respect to the atomic coordinate. As an illustration, the calculation
of forces coming from the nonbonded terms of the potential can given as[4]:
Fnb(rij) =
{(
1
4piε0
qiqj
εrr2ij
)
+ 4ij
[
12
(
σij
rij
)13
− 6
(
σij
rij
)7]}
rij
rij
(2.33)
2.3.3 Force field parameterisation
Currently employed force fields usually have all the necessary parameters required to
perform molecular dynamics simulations on proteins, nucleic acids, lipids, and carbohy-
drates which represent the most commonly encountered biomolecular systems. For this
reason force field parameter development focuses primarily on the building blocks of these
macromolecules as standard entries. From time to time however, there arises the need
to study nonstandard groups such as small molecule ligands, chemically derivitised forms
of standard groups of interest, or non-biological polymer systems. The nontrivial process
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of obtaining force field parameters for such nonstandard groups is what is referred to as
force field parameterisation, and it represents an advanced field in molecular simulation.
The parameterisation effort commences with first identifying the existing force field de-
scription to which the new parameters should agree. This ensures compatibility with
the existing potential description and eliminates unreasonable behaviour. Subsequently
parameters that already exist in the force field having the same (or in certain cases sim-
ilar) atomic properties, bond hybridisation, and chemical environment as existing in the
nonstandard molecules should be identified. This approach is known as parameterisa-
tion by analogy and benefits from a good chemical intuition and knowledge of organic
chemistry. In a great number of cases the required parameters already exist but not neces-
sarily in a single force field chemical entry. As illustration, the phenyl ring parameters for
phenylglycine, a nonstandard amino acid residue, maybe wholly sourced from the related
phenylalanine, but not from tyrosine because the hydroxyl group will have altered the
partial charges on the aromatic ring. In some cases, not all of the required parameters
that are available in the force field, making (high-level) QM calculations necessary for
parameter generation. This typically involves geometry optimisation at the appropriate
level of theory, followed by potential energy scanning along the internal modes of interest,
such as bonds or bond angles. The resulting energy profiles can then be used to deter-
mine the equilibrium values and force constants via fitting to the specific potential energy
function employed by the force field (equation (2.21)).
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Chapter 3
Amyloid beta peptide
3.1 Introduction
Amyloid beta (Aβ) polypeptide, a 4-kDa metallopeptide and principal component of
amyloid plaques found in the brains of Alzheimer’s patients, derives its name amyloid from
an initial description of it as a carbohydrate product, and beta to indicate its secondary
structural signature of β-pleated sheets. The self-aggregating peptide is an enzymatic
product of two secretases—the β and the γ secretases—acting on the parent amyloid
precursor peptide, a type-I transmembrane protein. The Aβ peptide is perhaps the most
important peptide involved in neurodegeneration, a reputation earned by its role in the
pathogenesis of Alzheimer’s disease. In 1987, the peptide was identified by Kang et al.
as the principal component of the amyloid plaque deposited in the brain of AD patients
[15]. It was later accepted widely as the single most important hallmark of the disease.
At that time the peptide was referred to as A4 protein. This, however, was not its first
discovery: four years earlier Glenner and Wong had reported the same peptide as the main
constituent of a vascular amyloid system[16]. Its distribution, however, is not exclusively
limited to the compact or diffuse senile plaques typically found in the hippocampal and
neocortical compactments of the brain, the peptide has also been isolated from the vascular
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tissues and generally in the central nervous system especially in the cerebrospinal fluid
[17–19].
3.2 The amyloid hypothesis
Initially different explanations for the development of Alzheimer’s disease were put forward
but it was only the amyloid-beta based hypothesis that best accounted for the different
pathological and biochemical events characterising the disease[20–26]. In the hypothesis,
elevated levels of the peptide in the cerebral cortex is considered as the trigger factor
for the development of AD pathology [27]. Increase in cerebral Aβ peptide results from
a disturbance in the fine balance between the generation and clearance of the peptide.
In other words, any event capable of altering Aβ peptide production or its clearance is
potentially a candidate in the initiation of such disturbance. And in fact, both aspects
are considered in attempts to design therapeutic agents aimed at rectifying the Aβ pep-
tide concentration anomaly in AD. The disruption of Aβ peptide level regulation in the
cerebral system (mainly though not exclusively) soon sets off a host of biochemical events
which ultimately results in the clinically observed systems typical of AD–cognition and
memory impairment[28].
The amyloid hypothesis has been widely accepted in explaining the specific details as-
sociated with AD mostly because it represents the model that most accurately fits the
different biochemical and functional changes accompanying the development of the dis-
ease. Some of the strongest evidence supporting the validity of the amyloid hypothesis
have come from Aβ toxicity studies, from the correlation of genetic mutations in the APP
and presenilin-1 and 2 genes, and from transgenic mice experiments. Aβ peptide was
shown to possess an aggregation-dependent neurotoxicity in cell culture studies, believed
to be an indication of the peptides toxicity in AD [29,30] The mutations associated with
Alzheimer’s disease pathology involve three main peptide systems–the amyloid precursor
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peptide, the presenilin-1 (chromosome 14) and presenilin-2 (chromosome 1) and finally
the apolipoprotein E lipoprotein (chromosome 19). Mutations in the amyloid precursor
peptide gene, though representing only a fraction of familial Alzheimer’s disease, have
been observed to involve sequence regions within the APP identified to correspond to the
Aβ peptide. An example is the London mutation in which a point mutation of codon 717
leads to an increased generation of Aβ42, an alloform of the amyloid peptide associated
with higher aggregation and neurotoxicity but normally produced in much lower titres
than what is seen in the London mutation of familial Alzheimer’s disease [31,32]. Another
strong evidence implicating Aβ as the main player in AD development comes from Down
Syndrome (DS) in which people with DS invariably develop AD if they live up to the 40
years [33]. The link between the two conditions arises from a triplication in DS of the
Chromosome 21 encoding the APP from which Aβ peptide is produced.
The strong correlation of amino acid substitutions involving the Aβ peptide sequence
with the pathology of Alzheimer’s disease further strongly establishes the causative role
of the peptide in disease development. Of special importance are point mutations involv-
ing glutamic and aspartic acids respectively at positions 22 and 23 of the Aβ peptide
sequence. Both assembly structure and clinical presentation of AD are strongly affected
by this group of mutations, which on a general note are associated with a faster aggrega-
tion kinetics and more aggressive symptom presentation. The Arctic mutation, involving
a change of Glu22 to a glycine (E22G) was reported to significantly increase Aβ prefibril-
lar structures and is associated with an early-onset pathology with a symptom complex
identical to the later-onset disease [34–37]. This is unlike the other mutations involving
Glu22 and Asp23 whose distinct structural and pathological signatures separate them
from the wild-type disease. Mutating Glu22 to either a lysine (E22K) as seen in the
Italian mutation or to a glutamine (E22Q) of the Dutch mutation results in a symptom
complex involving significant cerebral haemorrhage[38, 39]. Either the haemorrhage in
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the Dutch mutation, or the reported cerebral amyloid angiopathy [40] causes episodes of
cerebrovascular accidents (i.e. ischaemic or haemorrhagic stroke) with the attendant loss
of function of the area of the brain so affected. Both mutations are associated with the
formation of diffuse plaques and intensely increased polymerization rates; for instance,
the Italian mutant has been reported to be associated with twice as fast aggregation ki-
netic compared with the wild-type Aβ peptide [39, 41]. Lastly, diffuse plaque formation
as well as nonhaemorrhagic cerebral amyloid angiopathy have similarly been observed in
the Iowa mutation with aspartic acid 23 changed to asparagine (D23N)[38,42,43].
Presenilin-1 and 2 are part of the γ secretase enzyme complex that cleaves the APP
in regions corresponding to the Aβ C-terminus. While mutations involving the 4 vari-
ants of apolipoprotein E is associated with increased amyloid deposition in late-onset
Alzheimer’s disease, mutations in the presenilin-1 and 2 genes have been observed to shift
the C-terminal processing activities of γ-secretase in favour of Aβ42 over other less toxic
alloforms in early-onset AD[44,45]. Lastly, features akin to human AD such as gliosis, loss
of cerebral synapses and behavioural dysfunction have also been observed in transgenic
mice expressing the APP gene, but much less in mice lacking the apoE gene[45–47].
Criticism: At the turn of the century, when the amyloid hypothesis was just proposed
for explaining the pathogenesis of AD, the insoluble deposits were believed to be the prin-
cipal causative of the neurodegeneration associated with the disease. However, there is a
noticeable absence of the direct proof that amyloid plaque deposition is the major factor
that culminates in AD development. [48] And crucially, the observation that neurodegen-
eration occurs prior to the detection of amyloid plaques and the detection of the deposit in
nonsymptomatic or healthy persons represents a major disconnect between the amyloid
plaque-based hypothesis and clinical reality of the disease [49]. The available body of
evidence for the disease better points at the water-soluble prefibrillar aggregates as the
clinically relevant neurotoxic species rather than amyloid plaques whose deposition fail to
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sufficiently correlate with AD pathogenicity and progression[50]. This then led to a major
revision of the hypothesis to account for the observation that the water soluble oligomers
of Aβ are the main neurotoxic component[25]. The soluble Aβ oligomers not only demon-
strate significantly higher toxicities in cultured cells than the insoluble plaques, they also
reveal toxicity patterns that correlate better with AD pathology[51,52].
3.3 From structure to dysfunction: the mechanism
of toxicity
Following enzymatic cleavage from APP the generated small molecular weight amyloid-β
peptide undergoes a set of structural changes involving both intramolecular and inter-
molecular transitions, which two kinds of structural remodelling do not necessarily pro-
ceed independently. Prior to release from APP, the Aβ peptide adopts a predominantly
helical state inside the hydrophobic transmembrane environment, and after cleavage and
release into the aqueous extracellular medium it dynamically undergoes structural con-
versions in what is commonly believed to be an unstructured state in the monomer. At
this particular level attempts to unambiguously characterize the structural states of the
peptide have often been less than successful, largely a consequence of the rapid intrinsic
aggregation properties of the peptides under physiological conditions. While this has been
partly circumvented by employing artificial and nonphysiological experimental conditions,
including the use of nonpolar solvents, the obtained results cannot be safely extrapolated
to physiologic conditions. And this is where computational experiments have amply filled
in the gap.
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3.3.1 Aβ peptide
Based on intrinsic toxicity Aβ42 represents the most clinically important alloform of the
proteolytic products of β and γ secretases. The extra two residues in the C-terminus
confers subtle but important structural and toxicity properties on the peptide compared to
the most abundant but less amyloidogenic Aβ40 variant. The primary sequence of the full
length Aβ peptide features neighbouring subregions with sharply differing polar/solubility
properties, with the N-terminal portion largely composed of polar and hydrophilic residues
and the C-terminus lined up with hydrophobic residues. Within the mid-section is a short
hydrophobic stretch referred to as the central hydrophobic core (CHC). The very detail
of the ordering of the Aβ peptide sequence represents a vital driving force in the peptides
structural identity and by extension, its toxicity:
1DAEFRHDSG10YEVHHQKLVF20FAEDVGSNKG30AIIGLMVGGVV40IA.
The unique structural features of the peptide partly derives from its sequence constitu-
tion composed of six negative, three positive, and three histidine residues mostly in the
N-terminal half, and a predominantly hydrophobic C-terminal half. The peptide has an
isoelectric pH of 5.3 and under most experimental conditions has a negative charge surplus
at physiological pH values. Following cleavage by β– and γ–secretases and release into the
aqueous extracellular compartment, the peptide undergoes a sequence of conformational
transitions from being largely unstructured, to rapidly interconverting secondary struc-
tural units, and assembly into water-soluble structurally heterogeneous oligomers, and
ultimately to β-sheet-rich protofibrils and amyloid fibrils. The level of β-sheet formed
appears to be a characteristic feature that increases with aggregate size and stage.
The monomer is widely considered as an intrinsically disordered peptide. But rather than
being altogether unstructured, studies have shown that the monomers sample different
features in different parts of the sequence. For instance, studies by Yang and Teplow
revealed the two major variants as possessing a ”unique statistical coil” bearing identi-
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fiable secondary structure units, which are separated by turn structures[53]. NMR and
MD studies aimed at distinguishing between the two peptides revealed a higher rigidity
in Aβ42’s C-terminus[54, 55]. This was used to explain the higher amyloidogenicity and
neurotoxic potencies of Aβ42 compared with the Aβ40 [54, 55]. Other studies comparing
Aβ40 and Aβ42 have also revealed distinctions in their structures and aggregation prop-
erties[56, 57]. Nuclear Overhauser effect (NOE) measurements indicate both peptides as
exhibiting high conformational interconversion at the pico- to nanosecond time-scale[54].
The NOE values for Aβ42 C-terminus, however, suggested a higher rigidity compared
with Aβ40 [54]. This was believed to enforce some sort of conformational restriction that
keeps Aβ42’s C-terminal segment in a β-strand competent conformation. This in addition
serves an internal seeding function that translates into higher aggregation propensities in
the longer Aβ alloform. For instance, Yang and Teplow reported an increased C-terminal
residue contact with the CHC of Aβ42, which effect serves to better stabilize the β-sheet
structure more than in the shorter peptide, where the CHC would rather interact with
the N-terminus. Apart from the difference in primary amino acid sequences of the two
extra hydrophobic residues, Urbanc and co-workers identified a turn structure at sequence
positions Gly37-Gly38 in Aβ42 as another feature distinguishing it from the shorter pep-
tide[56, 57]. The Gly37-Gly38 turn has been suggested as an explanation for the relative
preference of Aβ42 for pentameric and hexameric oligomers, compared with the dimeric
assemblies more preferentially favored by Aβ40 [56,58,59]. A β-strand located at positions
Ala2-Phe4 has also only been exclusively identified in the Aβ40 [56].
The aggregation of Aβ monomers into toxic β-sheet-rich oligomer structures is believed
to depend to a significant extent on the sampled conformational state of the monomer
and factors influencing it. Metal ions, such as Cu2+, Zn2+, and Fe2+, lipid membranes,
the presence of preformed oligomers, hydrogen ion homeostasis as well as sample prepa-
ration conditions have been found to strongly influence both folding and the aggregation
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kinetics[60–65]. A weakly acidic pH (pH range 3.5-6.5) was suggested to be an important
factor promoting amyloid aggregation[60]. The protonation state of Aβ histidine residues
(His6, His13, and His14) is strongly influenced by pH changes with a change in net molec-
ular charge from –3 to 0 associated with a change from neutral to slightly acidic pH values.
It was found that pH-controlled structural changes can also be attributed to metal ion-
binding and to changes in the electrostatic charge distribution of the molecule[62]. For
instance, the binding of Cu2+ by Aβ28 was observed to be pH-dependent, with the diva-
lent metal ion inducing aggregation only at pH values lower than the physiological pH[61].
Whether it is by promoting metal coordination or by intrinsic redistribution of electro-
static charges, acidic pH values are likely to promote amyloid aggregation by decreasing
the hydrophilicity of the N-terminal portion of Aβ. Given the slightly acidic nature of
accompanying inflammatory response in AD,[66] acidic pH-facilitated aggregation is likely
to be of importance in disease development. It has been shown that brain from patients
who die from AD are more acidic than brains from patients who die suddenly with no
brain disease[67].
3.4 Aβ conformational sampling
The current section, written by me and corrected by Jun.-Prof Dr. Birgit Strodel, has
been published in the Journal of Physical Chemistry B[68] and has been cited here.
3.4.1 Initial configurations
The starting structures of the monomeric Aβ peptides, Aβ40 and Aβ42 were taken from
the RCSB Protein Data Bank (www.rcsb.org). The structure of Aβ40 (figure (3.1(a)))
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Figure 3.1: Aβ starting structures: (a) Aβ40 (PDB 1BA4), (b) Aβ42 (PDB 1Z0Q). The N and C termini are
represented as blue and red beads, respectively.
with accession code PDB 1BA4 [69] was solved in 1998 by solution NMR at a moderately
acidic pH 5.1 and in a micellar system composed of water–sodium dodecyl sulfate mixture.
It features largely unstructured N-terminal residues extending up to His14, after which
an α-helix involving a Gly25-Ser26-Asn27 hinge is adopted up to Val36. The employed
conditions more closely mimic a membrane or a membrane-aqueous system rather a pre-
dominantly aqueous system as modelled in the present work. The first of the ten NMR
structures deposited in the data bank was selected as starting configuration for MD in
explicit solvent environment. The simulation was designed to grant insight into the likely
conformational behaviour of the peptide in completely aqueous milieu, akin to what is
experienced in vivo after enzymatic cleavage, after which the peptide is released in the
extracellular compartment where aggregation into toxic oligomeric structures takes place.
Importantly, the choice of aqueous simulation conditions would provide an understanding
of the conformational profile of the monomer which expectedly serves as the foundation
for higher order structural organisation, and at the same time provide a structural refer-
ence for rationalising the observed differences in the closely related Aβ42 monomer whose
possession of two additional C-terminal residues has been proposed as the explanation for
the observed higher aggregation and neurotoxicity propensities[25,54].
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The starting structure for Aβ42 was also obtained from solution NMR-determined config-
uration obtained from the RCSB Protein Data Bank (figure (3.1(b)), accession code PDB
1Z0Q)[70]. The structural determination was performed in an apolar organic solvent,
hexafluoroisopropanol (HFIP) and the Aβ42 monomer was observed to adopt two helical
subunits, the shorter of which was sampled in the C-terminal segment of the peptide.
Using a combination of CD and NMR spectroscopies, the effect of increasing water con-
centration up to 99%v/v was probed and observed to involve reversible conversion of the
predominantly C-terminal helix at high HFIP concentration to β-sheet–rich conformation
at water levels greater than 80%v/v[70]. As long as the apolar HFIP was present however,
the N-terminal helix was retained leaving the important question of what conformations
would be adopted in a completely aqueous environment. The significantly high aggre-
gation propensity of the peptide has, however, prevented conventional experiment from
being able to address the question. And this is where molecular dynamics simulation
provides a powerful method of investigating the peptide’s conformational experience in
100%v/v aqueous system: the very fact that a single molecule can be studied, immedi-
ately circumvents the high aggregation propensity challenge.
3.4.2 Simulation details
The relevance of a force field crucially depends on its parameterisation scheme and em-
ploying it for systems for which it was not originally designed should be done with caution.
This, for example, applies to most protein force fields whose parameter development were
based on small non-protein compounds. One way this work has selected to reduce force
field peculiarities is by employing two different force fields for each protein system–the
GROMOS force fields ffG43a2 parameterised to reproduce experimental heat of vapor-
isation of small molecules [71], and ffG53a6 parameterised to reproduce experimental
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solvation enthalpies for small molecules. [9]. Both are united-atom force fields which en-
sures sufficient similarity in overall force field structure, and the simulation results from
each were validated against experimental NMR chemical shift data (discussed below). A
cubic simulation box was set up for each of the Aβ40 and Aβ42 monomers, and the peptide
centered inside with a 10 A˚ minimum distance allowed between each atom and the edges
of the box giving a box length of ≈ 65 A˚. A rather large box was chosen so as to avoid
artefacts resulting from the constraining effect of smaller box types preventing protein
unfolding[72]. Artefacts from edge effects (unnatural edge truncation) resulting from the
use of a finite system, however, remains and in order to reduce this effect, a periodic
boundary condition (PBC) was applied across the box edges. This entails surrounding
the simulation box with the translated copies (periodic images) of itself in the xyz direc-
tions closely resembling a boundless situation[4]. There is a special implication to this, the
possibility of simulated particles to be surrounded by multiple copies of itself which calls
for a special way of handling nonbonded interactions. In GROMACS, the minimum image
convention method is employed, that involves computing the short-range component of
the nonbonded interaction for only the closest periodic image. The choice of a cut-off
radius smaller than half the box vector for a cubic box (the smallest of the box vectors
for noncubic boxes) ensures that a maximum of one copy of the particle is considered for
short-range interactions. The Particle Mesh-Ewald method, a lattice sum approach, was
employed for calculating the long-range component of the coulombic interactions. A 14
A˚ cutoff was used for truncating the short-range electrostatic (also van der Waals) forces.
Following steepest descent energy minimization of Aβ40 (and Aβ42) in vacuo, sufficient
water molecules, using the simple point-charge (SPC) water model were added to fill the
simulation box. The choice of protonation states for the ionizable residues to mimic the
near-neutral physiological pH of 7.4 produced a −3 net charge per molecule. This involves
protonating basic groups – Arg5, Lys16, Lys28 and the N-terminus, while deprotonating
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the acidic groups Asp1, 7 , 23, Glu3, 11, 22 and the C-terminus. Counter ions, Na+ and
Cl−, were randomly added to neutralise the net molecular charge while at the same time
achieving a NaCl concentration of 150 mM. The addition of solvent often leaves pockets
of empty spaces within the system, while at the same time there is the possibility of
placing a solvent molecule too close to the peptide (that is, violating the van der Waals
radius). Both phenomena results in high system energy, and it is crucial to first bring
the system as close to equilibrium as possible before performing the production MD run.
For this reason, the solvated system was first subjected to 5000 steps of steepest de-
scent minimisation followed by 5000 steps of conjugate gradient minimization. This was
followed by position-restrained dynamics performed for 1 ns, during which a harmonic
restraining force of 239 kcal/mol was placed on each coordinate of the peptide’s heavy
(i.e., non-hydrogen) atoms, allowing the solvent molecules to relax around the restrained
peptide. This serves as a very efficient means of removing bad contacts remaining af-
ter the energy minimisations steps, thus bringing the system near equilibrium conditions.
The position-restrained dynamics was performed under constant temperature (300 K) and
pressure (1 bar) conditions (i.e., NPT ensemble) involving a coupling of the system to a
Berendsen thermostat and barostat, respectively. After turning off the position restraints,
and replacing the temperature and pressure coupling respectively with the Nose´-Hoover
thermostat and a Parrinello–Rahman barostat, the system was subjected to a 1.5 µs MD
production run. Neighbour list generation, that is the dynamic (static over the number of
steps used in updating the list) list defining neighbouring atoms for computing nonbonded
interactions, was updated every 10 ps using a cutoff radius of 1.4 nm. Coordinates were
saved every 20 ps, and after completion the trajectories were analysed.
System in the simulation setup description stands for each of Aβ40–ffG43a2, Aβ40–ffG53a6,
Aβ42–ffG43a2, and Aβ42–ffG53a6 peptide-force field combinations. That is, an aggregate
of 6.0 µs MD simulation in explicit solvent was performed for a comparative study of the
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conformational behaviour of the two Aβ monomers as well as for determining the accu-
racy of the force fields at describing the two Aβ peptides’ dynamics. Each simulation was
performed using 64 cores of the Ju¨lich Supercomputer Centre’s (JSC) JUROPA computer
cluster. The use of virtual hydrogen sites allowed the use of a simulation timestep of 5 fs,
and a simulation time of approximately fifteen days for each system.
3.4.3 The structure of Aβ40
In order to monitor the transition of the peptide’s secondary structure, the program
DSSP [73] that employs hydrogen bond definition in addition to information from ge-
ometric pattern analysis, was employed. Interfacing of GROMACS with DSSP allows
the secondary structure transition to be obtained as a function of simulation time. The
DSSP plot for ffG43a2 (figure 3.2) shows a retention of the N-terminal α-helix, while the
C-terminal-ward edge underwent a conversion into turns and β-strands within the first
20 ns. Between 20–90 ns the α-helix was partly converted to pi-helix involving residues
13–25, which between 140 and 340 ns reduced to residues 13–18. Relative to the other
residues of the peptide and according to the force field, residues 13–25 seem to possess
a high helical propensity, which gradually converts between the α-helical form obtained
in apolar medium (HFIP) to pi-helical in 100% completely aqueous medium. Conversion
between the helical forms represents gradual destabilisation of the helix which eventually
was converted into turns between 900–1100 ns. The N-terminal residues 1–14 on the
other hand remained largely disordered throughout the 1.5 µs-long trajectory, only fleet-
ingly sampling α-helix (for instance, the boundary residue 13) and β-bridge in the second
half of the simulation. β-structures were also sampled, involving the C-terminal residues
28–39, separated from the helical CHC by a coil structure involving Gly25-Ser26-Asn27.
Residues 30–31 and 34–35 existed as turns.
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Simulation with the ffG53a6 parameter set produced certain differences in the confor-
Figure 3.2: DSSP plot showing secondary structure transition in Aβ40 as modelled by ffG43a2. The structural
pattern involves three distinct segment-based conformations with N-terminal up to residue 14 sampling turns
and bends; a stable α-helix is sampled involving residues 16 to 24 of the peptide; and residues in the C-terminal
segment forms β-sheet structure.
mations sampled by Aβ40 (figure 3.3). With ffG53a6, the helix in the CHC completely
disappeared after 600 ns. Also notable is the fact that participation of residues in the helix
was limited to just residues 10–14. The initial 200 ns saw the C-terminal section undergo
structural transitions involving helix, β-strands and disordered conformations. From 200
ns on a β-strand was more stably sampled between residues 19–23 and 32–37, while 24–31
for the most part remained disordered. To a large extent the N-terminal residues did not
form a β-strand: between t=0 and t=600 ns residues up to 10 were disordered, which for
the rest of the simulations increased to residues 1–17. In general, the appearance of the
DSSP-obtained secondary structure plots for Aβ40 indicates a higher structural flexibility
for ffG53a6 than for ffG43a2 in which sampled structures generally persisted longer.
To better describe the structural states sampled by the force fields, cluster analysis was
Figure 3.3: DSSP plot showing secondary structure transition in Aβ40 as modelled by ffG53a6.
performed on each trajectory using the method by Daura et al. [74]. This involves the
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pooling together of all the sampled configurations in the trajectories, and counting the
number of structures (neighbours) within a predetermined cutoff radius. The structure
with the highest number of neighbours which together with its neighbours constitute a
cluster, is then eliminated from the pool alongside its neighbours. The process is re-
peated until all the structures have been assigned to clusters. Using a 2 A˚ cutoff for the
backbone atoms, and the last 1.0 µs of the trajectories (chemical shift analysis, discussed
below revealed the trajectories as having equilibrated after t=500 ns), cluster analysis was
performed. Figure 3.4 presents the central structures for the five largest clusters for each
force field. Before discussing the result from the cluster analysis, it should be noted that
an instance of secondary structure assignment conflict occurred in figure 3a, involving
a pi-helix assigned by STRIDE (the secondary structure assignment algorithm used by
VMD, the employed graphic programme) for residues 28–36 to which DSSP assigned a
strand-turn-strand-turn structure. No other instance of assignment conflict was observed
and for consistency the assignment by DSSP has been adopted in this work.
Results of the cluster analysis significantly capture the structural changes featured in
Figure 3.4: Aβ40 structures for the centers of the five most populated clusters obtained from the last 1000 ns of
the MD simulations using ffG43a2(a) and ffG53a6(b) with the cluster size decreasing from (i) to (v). The blue
and the red spheres respectively show the N- and C-termini. pi helix, β-sheet, and β-bridge regions are shown in
purple, red and black respectively, while the yellow and while regions are unstructured.
the DSSP plots (figures 3.2 and 3.3). In the case of ffG43a2 the five largest clusters
represent 94% of all the sampled configurations while for ffG53a6 only 26% of the sam-
pled configurations were contained in the five clusters, indicating a higher conformational
flexibility in the latter force field compared to the former. The DSSP plots suggest that
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the N-terminal region contributes significantly to this flexibility difference. An overlay of
the root mean square fluctuations of the backbone atoms in figure 3.5 indicates a much
higher structural flexibility in the peptide when simulated with ffG53a6. This may also
Figure 3.5: Root mean square fluctuation of the backbone atoms of Aβ40 showing higher peptide flexibility with
ffG53a6 (red) compared with ffG43a2 (black).
be described as ffG53a6 favouring disordered states for Aβ40, which better correlates with
the expectation for Aβ monomers. The cluster centres for ffG53a6 feature a largely disor-
dered N-terminal segment and a β-strand involving two sequence stretches, 19FAED23 of
the CHC self-recognition unit, and 32IGLMVG37 belonging to the C-terminal hydrophobic
patch. The terminal three residues, 38GVV40, exist as disordered in all five clusters. This
partly agrees with the structural model proposed by Danielsson et al. from 15N relaxation
data.[75]. Using persistence lengths obtained at temperatures ranging from 3 to 18◦C, a
model composed of six structurally distinct units was proposed for Aβ40 involving a pi-
helix for residues 1–4; a coil structure between residues 5–10; a second pi-helix for residues
11–15; a β-strand for residues 16–24; a second coil involving residues 25–30; and finally
a β-strand involving C-terminal hydrophobic residues 31–40. In the ffG53a6 simulation,
the observed unstructured region involving residues 1–18 and 24–31 and the β-strand of
residues 19–23 (16–24 in the experimental model) and 32–37 (31–40 in the experimental
model) are in agreement with the proposed NMR relaxation model. The exception is the
pi-helix involving residues 1–4 and 11–15, which was not found to be stable in the ffG53a6
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simulation of Aβ40.
3.4.4 The structure of Aβ42
As presented in figure 3.6, the plots of the secondary structure of Aβ42 obtained with
ffG43a2 reveals a pattern similar to that obtained for the shorter peptide, especially in
the formation of a relatively stable N-terminal helix. However, in the present case, a pi-
helix (rather than an α-helix) between residues 5–15 is observed. Between ca 370 and 840
ns, the mid-section region spanning residues 20–30 support a strand–turn–strand confor-
mation. This structure was subsequently replaced by a disordered state, while sequences
spanning residues 33–40 and 2–4 sampled β-strands.
With the ffG53a6 force field, the two helical units present in the NMR starting structure
Figure 3.6: DSSP plot showing secondary structure transition in Aβ42 as modelled by ffG43a2.
were completely lost within 100 ns (figure 3.7), suggesting a much higher conformational
flexibility than observed with ffG43a2. This, however, does not indicate inability to sam-
ple specific conformations. Based on sampled β-strand–coil features, the trajectory may
be viewed as being temporally divided into four stages. In the first 400 ns residues 24–
40 intermittently but continually sample β-strand structure while residues 1–23 remain
largely disordered. During the next 325 ns, the N-terminal section stably sampled β-
strand while the remaining residues (i.e. covering the CHC and the C-terminal sections)
adopted disordered states. Between 725 ns and 1250 ns, the peptide again adopts a
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structure characterised by the C-terminal region adopting β-sheet state and disordered
N-terminal residues. The first 1250 ns thus sees β-sheets sampled interchangeably and
with a mutual exclusivity by the two half segments of the peptide. During the last 250
ns, however, the β-sheet additionally extends to the N-terminal residues 6–13.
As for Aβ40, cluster analysis was performed on the last microsecond of the MD tra-
Figure 3.7: DSSP plot showing secondary structure transition in Aβ42 as modelled by ffG53a6.
jectories with the same 2 A˚ RMSD cutoff. In agreement with the secondary structure
plot for ffG43a2, the five cluster centres (Figure 3.8) adopt an extensive N-terminal pi-
helix spanning residues 4–16. The five largest clusters for ffG43a2 represent 76% of
all sampled configurations indicating a higher conformational rigidity compared with
ffG53a6, in which 48% of all structures are captured in the five clusters. In the case
of ffG53a6, the cluster centers mostly feature β-sheets involving residues 3EFRHDSG9,
residues 17LVFFAE22 – the CHC self-recognition unit – and the C-terminal hydrophobic
stretch 30AII GLMVGGVV40 where the italicised residues are disordered. In 2004, Ur-
banc et al. identified the disordered 36VGG38 as distinctly characteristic of Aβ42 where it
forms a hinge[56]. In agreement, the ffG53a6 force field correctly identified the hinge at
36VGG38 in Aβ42.
From the relative size of the five most populated clusters, it becomes obvious that the
observed pattern of conformational flexibility arises from the force field rather than solely
from the simulated peptides. As observed above for the shorter peptide, Aβ42 monomer
also undergoes a higher structural dynamics when simulated with the ffG53a6 as shown
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Figure 3.8: Aβ42 structures for the centers of the five most populated clusters obtained from the last 1000 ns of
the MD simulations using ffG43a2(a) and ffG53a6(b) with the cluster size decreasing from (i) to (v). The blue
and the red spheres respectively show the N- and C-termini. pi helix, β-sheet, and β-bridge regions are shown in
purple, red and black respectively, while the yellow and while regions are unstructured.
in the backbone RMSF plot in figure 3.9.
Figure 3.9: Root mean square fluctuation of the backbone atoms of Aβ42 showing higher peptide flexibility with
ffG53a6(red) compared with ffG43a2 (black).
3.4.5 Comparison of Aβ40 and Aβ42
The extra two residues distinguishing the primary sequence of Aβ40 and Aβ42 have been
indicated to confer significant differences on both the conformation and aggregation prop-
erties of the two peptides[56, 57]. Both peptides were shown by NOE measurements to
undergo a high conformational interconversion at the ps-to-ns time-scale; however, higher
NOE values were obtained for the C-terminus of Aβ42 indicating a relatively more rigid
C-terminus than for the shorter peptide[54]. This was proposed to maintain Aβ42’s C-
terminus in a β-strand conformation which acts as an internal seed for amyloid aggre-
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gation. The diglycine turn (Gly37-Gly38) turn was only identified in Aβ42, which was
proposed as a distinguishing feature of Aβ42 since it was not found in Aβ40 [56,57]. This
was used to explain the preference of Aβ42 for pentamer and hexamer formation, compared
with Aβ40 which would rather aggregate into dimeric structures [56, 58, 59]. A β-strand
was also uniquely identified between Ala2–Phe4 in Aβ40 [56].
Our simulations present the two peptides as largely unstructured in their first 10 residues
(N-terminal). In comparative terms however, Aβ40 appears to be more disordered in this
segment than Aβ42, which additionally samples either pi-helix and β-strands in its N-
terminal residues. Both force fields successfully predict β-strands in the β-sheet-forming
self-recognition sequence 17LVFFAE22 of Aβ42. In Aβ40, only ffG53a6 predicts β-strand
and only in the vicinity of the self-recognition unit involving 20FAED23. The 16KLVFF20
motif is widely accepted as the first key motif for nucleating Aβ aggregation [76], being
one of two hydrophobic stretches present–17LVFFA21 and 30AIIGLMVGGVV40IA42. The
simulations for both peptides additionally reveal Gly25–Asn27 as constituting some sort
of a bridge, which conformationally separates the two hydrophobic patches. In agree-
ment with the suggestion that a conformational transition from helix to coil precedes the
characteristic β-sheet-dependent aggregation of Aβ [70], both force fields predict the com-
plete loss of the helix in the second hydrophobic patch of both peptides. The C-terminal
segments of both peptides sampled a β-strand conformation; however in agreement with
earlier studies the hinge 37GG38 identified as characteristic of the longer peptide[56, 57]
was sampled only in Aβ42.
Furthermore, the ffG53a6 simulation showed Aβ42 as capable of sampling β-strand in its
N-terminal, mid-sequence, and the C-terminal segments, although the last two segments
were significantly better able to do this. This compares with Aβ40 in which β-strands
were largely limited to the last two segments, and that to a much lesser degree. The five
clusters obtained from ffG43a2 for Aβ42 feature an extensive pi-helix spanning sequence
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spanning residues 4–16, which slightly contrasts with the prefential sampling of α-helix in
Aβ40, but strongly contrasts with the stabilisation of disordered structure and β-strands
predicted by ffG53a6. Both force fields however indicate a higher β-sheet propensity
for Aβ42 than Aβ40. Thus, by using two force fields based on different parameterisation
philosophies we have been able to identify peptide-based structural properties.
The terminal residues of both peptides adopt a coil structure. However, while these in-
Figure 3.10: A pictorial representation of the relative structural flexibilities of Aβ40 and Aβ42 and the influence
of force fields: (a) Aβ40 with ffG43a2, (b) Aβ40 with ffG53a6, (c) Aβ42 with ffG43a2, (d) Aβ42 with ffG53a6.
For a description of the figure, see text below.
volve three residues of Aβ40, only two of Aβ42 exist as coil. This perhaps is an indication
of a higher C-terminal stiffness reported for the longer peptide [54]. Comparing the per-
centage representations obtained in the cluster analyses of the two peptides is instructive
in further capturing the influence of the extra two residues in Aβ42. With ffG53a6, 48% of
the sampled frames were captured in the five biggest clusters of Aβ42 and 26% for Aβ40,
which demonstrates Aβ42 as being more rigid than Aβ40. This supports the findings of
Yan and Wang, who, through experimental measurements, found Aβ42 to be more rigid
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at its C-terminus than Aβ40 [54]. On the other hand, ffG43a2 supports a more rigid
Aβ40, with 94% structures within the five largest clusters, compared with 76% in Aβ42.
An estimate of the relative rigidity can be determined from the cluster analysis results.
Figure 3.10 shows a pictorial representation using information from cluster analyses to
distinguish between the observed peptide- and force field-based differences. Each of the
four peptide-force field systems is represented by a blue boundary (dimensionless) within
which all sampled conformations are represented by the 10 black dots. The conformations
falling within the five largest clusters are shown inside the black circles. The number of
conformations within and without the black cycles provides a simple means of comparing
the behaviour of both the peptides and the force fields. The degree of force field bias
for the folded state, for example, can be estimated using the number of clusters falling
outside the black circles. For instance, ffG43a2 is about 7 times and 2.5 times less likely
to sample disordered conformations compared with ffG53a6 for Aβ40 (figure 3.10(a) vs
(b)) and Aβ42 (figure 3.10(c) vs (d)) respectively. Vertical comparison on the other hand
presents the differences between the two peptides, with ffG43a2 showing Aβ40 to be about
2 times more rigid than Aβ42 (figure 3.10(a) vs (c)) against experimental findings[54]. In
figure 3.10(b) and (d) on the other hand and in agreement with experiment findings[54],
ffG53a6 supports a slightly higher Aβ42 conformational rigidity, about 1.4 that obtained
for Aβ40.
3.4.6 Experimental validation using chemical shifts
The simulation results presented above suggest there are significant force field biases in the
conformational study of the two Aβ peptides. One possibility of identifying which force
field is biased towards which type of secondary structure (e.g., helical, coil and β-sheet)
is by assessing the convergence of the trajectories with respect to experimental data. For
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this we have chosen solution NMR chemical shifts which were determined in the group of
Prof. Zagorski at the Department of Chemistry, Case Western Reserve University, Cleve-
land, USA[77]. It should be noted that the determination of the NMR chemical shifts at
278 K rather than at 300 K as employed by our simulations, may slightly but not greatly
affect the results since both studies employ the same pH and aqueous conditions.
We calculated the N, HN, Cα, and Cβ chemical shifts (δcalc) using the programme
CamShift that employs the dependence of chemical shift on conformation as a function
of intramolecular atomic distances expressed as a polynomial expansion[78]. See section
3.7 for additional information on CamShift. CamShift takes individual coordinate files as
input for the prediction, which we adapted to work on trajectories by taking snapshots
at every 50 ps and performing the shift calculation. We then calculated the deviation ∆δ
of δcalc from the δexp for the entire 1.5 µs trajectories for each Aβ peptide. Figure 3.11
shows the time evolution of δcalc and ∆δ for the Cα atoms, while table 3.1 presents the
∆δ for each 500 ns time-block for the selected four atom types. We base the acceptability
of the calculated ∆δ values on the published values for a test set of protein in which
CamShift was shown to be of comparable accuracy as other chemical shift predictors[78].
The reference ∆δ data have also been presented in table 3.1.
The data obtained for the four chemical shift types (N, HN, Cα, and Cβ) show the ∆δ
values as being within the expected deviations, in particular for the force field ffG53a6.
The discussion of the results, from this point on until the end of italicization, is cited
as excerpt from our work, Olubiyi OO, Strodel B, Journal of Physical Chemistry 2012,
Volume 116, pages 3280-91, 2012:
”The ∆δ for Aβ40 and Aβ42 modeled with ffG43a2 show that this force field is not fully
able to reproduce the experimentally determined shift values. Although δcalc for HN and
Cβ are generally consistent with the experimental values (ffG43a2 and ffG53a6), the ∆δ
for the amide N and Cα shifts reveal that these shifts really converged to the experimental
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values only for the simulations with ffG53a6. With ffG53a6, the average ∆δ for the N
and Cα shifts are generally below the expected deviation for simulation times longer than
500 ns. Only for Aβ40 with ffG53a6, ∆δ for the N chemical shift is slightly above 3.01
ppm between 500 and 1000 ns; it decreases to values below 3.01 ppm for simulation times
above 600 ns. This decrease in ∆δ coincides with the conversion from a helical to coil
state in the N-terminal segment around 600 ns (figure 3.3) .
In Aβ42 (ffG43a2), a transition from coil to β-strand is observed for some N-terminal
Figure 3.11: ∆δ values between δcalc and δexp plotted against time for (a) Aβ40 with ffG43a2, (b) Aβ40 with
ffG53a6, (c) Aβ42 with ffG43a2, (d) Aβ42 with ffG53a6. Values for the amide N, Cα, Cβ and HN atoms are shown
in blue, red, turquoise and green with the CamShift published deviations for the protein test set represented with
horizontal lines. Deviations of the δcalc from δexp for the Cα atoms (i.e., ∆δ=δcalc- δexp) using the last 1000 ns
are shown for (e) Aβ40 with ffG43a2, (f) Aβ40 with ffG53a6, (g) Aβ42 with ffG43a2, (g) Aβ42 with ffG53a6.
residues around 400 ns (figure 3.7), which causes ∆δ to decrease considerably at this time,
that is, better agreeing with experimental data. This finding supports our approach to use
500 ns as the boundary between the equilibration and the production phases for the analy-
sis of our MD simulations. For the ffG43a2 simulations, however, it becomes evident that
the ∆δ values do not decrease during the last 1000 ns of the MD trajectories; in some
cases, they even increase, showing that this particular force field does not correctly sample
the experimentally observed structures.
To get insight into which of the residues cause the deviation of δcalc from δexp, we com-
puted for the last 1000 ns of the MD trajectories, the average δcalc values for Cα,
〈
δcalc
〉
,
and plotted these against δexp in Figure 3.12. And we calculated the difference between〈
δcalc
〉
and δexp: ∆δ =
〈
δcalc
〉 − δexp. The results for ∆δ are shown in figure 3.11. For
the simulation of Aβ40 with ffG43a2, it becomes obvious that large deviations between
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〈
δcalc
〉
and δexp ( |∆δ| > 1 ppm) occur for almost all residues between residues 7 and 35.
Particularly striking is the overestimation of
〈
δcalc
〉
between residues 13 and 23, whereas
for the other residues, we observe an alternation of over- and underestimation of
〈
δcalc
〉
,
for example, from residues 7 to 12 and from 28 to 35.
Since Cα atoms experience a relative upfield shift when the residue in question is in-
Force field Peptide Time (ns) N(3.01) HN(0.56) Cα(1.30) Cβ(1.36)
ffG43a2
Aβ40 0→500 3.95 0.40 1.79 1.09
Aβ40 500→1000 4.01 0.40 1.76 1.09
Aβ40 1000→1500 4.19 0.41 1.77 1.07
Aβ42 0→500 3.87 0.43 1.69 1.17
Aβ42 500→1000 3.64 0.46 1.49 1.20
Aβ42 1000→1500 3.51 0.44 1.43 1.26
ffG53a6
Aβ40 0→500 3.71 0.35 1.46 1.13
Aβ40 500→1000 3.08 0.33 1.16 1.27
Aβ40 1000→1500 2.87 0.34 1.12 1.44
Aβ42 0→500 3.40 0.36 1.24 1.22
Aβ42 500→1000 2.68 0.35 1.30 1.19
Aβ42 1000→1500 2.74 0.37 1.18 1.30
Table 3.1: |∆δ| table for the amide N, Cα, Cβ and HN atoms. For comparison, ∆δ values published for CamShift
using a test set of proteins are presented in parentheses.
corporated into an α- or pi-helix [79, 80] or a turn region,[79] we conclude that in the
regions with ∆δ > 1 ppm, one of these secondary structures is overstabilized by ffG43a2.
Indeed, the DSSP plot in figure 3.2 shows a rather stable α-helix between residues 13 and
23 in Aβ40. From
15N relaxation data, a structural propensity for pi-helix was predicted for
residues 11-15 in Aβ40. However, from the comparison of the Cα shift results, it becomes
obvious that ffG43a2 overestimates the N-terminal helical stability in Aβ40. This helical
stability leads to a reduction of the conformational flexibility of the Aβ peptides, as the
high population of the first five clusters from the ffG43a2 simulations revealed. A too-
small computed Cα shift is indicative of an overstabilization of β structure as Cα protons
experience a relative downfield shift when incorporated into a β-sheet[79]. The alterna-
tion of too-high and too-low shifts between residues 7-12 and 28-35 is thus a result of the
overestimation of successive turn and β conformations, respectively. This conclusion is
underpinned by the DSSP plot in figure 3.2.
In summary, ffG43a2 does not provide a satisfactory model for the conformational dy-
namics of Aβ40. For Aβ42, the ffG43a2 result is better, especially for the C-terminal part
from residue 17 onward, for which most |∆δ| values are <1 ppm. However, for residues
5-16, we observe an overstabilization of the N-terminal pi-helix (figure 3.6), leading to
∆δ > 1 ppm in this region. According to our chemical shift analysis, ffG53a6 provides a
better description for both Aβ40 and Aβ42. Most of the |∆δ| values are <1 ppm. Note-
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worthy exceptions are residue 22 in Aβ40 and residues 6, 12, and 30 in Aβ42, for which
the β content is slightly overestimated. Our comparison between experimental and simu-
lated chemical shifts is of similar performance as the same kind of analysis in ref [81], in
which the simulated shifts were obtained from replica exchange MD simulations of Aβ40
and Aβ42 using the AMBER99SB force field[81] with implicit solvation. The representa-
tive structures obtained by Yang and Teplow also show similarities to the most important
cluster structures, which we obtained with ffG53a6 [53].
In summary, from the comparison between calculated and experimental chemical shifts,
Figure 3.12: Comparison of |∆δ| (red) and δexp (black) using Cα atoms for (a) Aβ40 with ffG43a2, (b) Aβ40
with ffG53a6, (c) Aβ42 with ffG43a2, and (d) Aβ42 with ffG53a6.
we can conclude that ffG53a6 is better able to model the intrinsically disordered Aβ peptide
than ffG43a2, which overstabilizes the helical state in the N-terminal half of the sequence
and underestimates the overall conformational flexibility of the peptide. This finding is
contrary to the performance of ffG43a2 and ffG53a6 for folded proteins, in which ffG43a2
was found to be better able to maintain folded structures and generally provides a good
balance between helical and β folds[82]. The superiority of ffG53a6 for modeling Aβ may
be due to the fact that this force field was solely parametrized to reproduce the free en-
thalpies of hydration and apolar solvation for a range of compounds[83].
The relative free enthalpy of solvation between polar and apolar environments is a key
determinant in many biomolecular processes of interest, such as protein folding and ag-
gregation or membrane formation and transport over membranes. Thus, the folded protein
state in ffG53a6 results from the choice of the parameter set and not vice versa. In a re-
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cent study, it was shown that the common protein force fields (ffG53a6 was not included)
are generally able to correctly predict the rate of folding and the structure of the native
state[84]. The folding mechanism and the properties of the unfolded state, however, were
found to depend substantially on the choice of force field. This finding, as well as other
force field studies for Aβ peptides,[55] demonstrate the need for proper benchmarking of
the protein force fields for unfolded and intrinsically disordered proteins.”
3.5 The effect of pH on Aβ
Various studies conducted on the effect of pH variation on the structure of Aβ have
indicated that the protonation states of the three histidine residues in Aβ (His6, His13
and His14) are crucial in explaining the role of pH [61, 85, 86]. And in fact, histidine
residues have been suggested to sensitise the peptide to metal ions binding, as revealed
in mutation studies in which His substitution resulted in reduced Aβ aggregation in the
presence of aggregation-promoting Cu2+ and Zn2+ [61,85,86]. In this section the effect of
pH variation on the structural dynamics of the two Aβ monomers is discussed.
The pH of a system can be defined as the negative logarithm of the molar concentration
of protons present:
pH = − log[H+] (3.1)
Since subatomic units like electrons and protons may only be accurately captured using
quantum descriptions (and this not without a prohibitive cost in terms of computational
resources for modelling systems containing 30,000 atoms or more), we have employed a
classical description in modelling different pH conditions. This essentially involves the
choice of the ionisation states of Arg5, Lys16, Lys28, Asp1, Asp7, Asp23, Glu3, Glu11,
Glu22, His6, His13, His14 and the N- and C-termini to mimic four pH conditions: an
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acidic pH, an isoelectric pH, the physiologic pH and a basic pH (table 3.2).
pH 2.0 5.0 7.4 8.0
R5 +1 +1 +1 0
K16 +1 +1 +1 0
K28 +1 +1 +1 0
D1 0 −1 −1 −1
D7 0 −1 −1 −1
D23 0 −1 −1 −1
E3 0 −1 −1 −1
D11 0 −1 −1 −1
D22 0 −1 −1 −1
H6 +1 +1 0 0
H13 +1 +1 0 0
H14 +1 +1 0 0
N-Term. +1 +1 +1 0
C-Term. 0 −1 −1 −1
Net Charge +7 0 −3 −7
Table 3.2: Modelled ionisation states for residues and termini of Aβ42.
3.5.1 Simulation setup, models and analyses
Histidine is neutral (also referred to as deprotonated) when protonated only at the δ nitro-
gen of the imidazolyl sidechain, and positively charged (protonated) when the  nitrogen
is additionally protonated. Using an MD protocol similar to that described in 2.4.2, 1
µs production runs were performed for each modelled pH and for each peptide-force field
combination. That is, an additional 6 µs of simulations time was cumulated; while the
first 1 µs from the 1.5 µs trajectories discussed above were used for the physiologic pH. All
simulations were performed at 300 K and 1 bar, using an explicit solvent representation
and an isothermal-isobaric ensemble that closely reflects standard laboratory conditions.
Although the simulations were performed with both ffG43a2 and ffG53a6, only results for
the latter force field are discussed since ffG43a2 was already shown (above) to suffer from
a significant structural bias. Furthermore, test simulations for ffG43a2 revealed that the
pattern of variations as a result of pH changes, was captured in a similar manner to that
of ffG53a6 [68].
To provide an explanation for the differences in the observed dynamics of the peptide
under the considered pH conditions we performed contact map analyses for the four tra-
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jectories with a truncation distance of 15 A˚ at 0 ns, 300 ns, 600 ns and 1 µs. In order
to account for sidechain as well as backbone contributions, all the atoms in the protein
were included while constructing the maps. Figure 3.13 presents the contact maps. Each
resulting pattern in figure 3.13 may be taken as a fingerprint of Aβ42 monomer’s tertiary
structure for the particular pH state. In this regard, helical and β structures are the easiest
to identify. Helical structures present a diagonal pattern involving residues i+ n running
parallel to the self-contact axis. For 310-, α-, and pi-helices, n is respectively 3, 4 and 5.
Thus helices appear in the map as interactions involving a maximum of 5 neighbouring
residues. Extended antiparallel β-sheet structures on the other hand involves off-diagonal
interaction, the length and number of which respectively signify the extent and number
of the β-sheet. Random coil lacks the discernible patterns of helical and β structures.
To better compare the sampled structures we performed DSSP analyses which we have
restricted to the final 500 ns of each trajectory at which time the peptide is considered to
have equilibrated.
3.5.2 Effect of pH on Aβ42 secondary structure
For all four systems, at time t = 0 the peptide features a pattern representing helical
conformation derived from the starting structure. By 300 ns, the contact maps have
become substantially different for each pH. The peptide has almost entirely lost its helices
at pH 5.4 and 7.4 while they continued to be sampled at pH 2.0 and 8.0. This appears
to be a separation in dynamics based on Aβ42’s net-charge, whereby the peptide’s helices
are retained under high charges of ±7 and lost at lower charges of 0 (pH 5.4) and −3 (pH
7.4). Visual inspection of the structures in figure 3.15 further shows that at 300 ns, pH
5.4 and 7.4 the helices have been replaced by coils and β-sheets. While the peptide is able
to form β-sheets under all four modelled pH values as shown in the DSSP plot in figure
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Figure 3.13: Contact maps for Aβ42 monomer at pH 2.0, 5.4, 7.4 and 8.0 using conformations sampled at 0 ns,
300 ns, 600 ns, and 1000 ns.
3.14, β-sheets at pH 2.0 and 8.0 are mostly limited to residues 33 to 42 with a turn at
29GAII32 (pH 2.0) or 27NKGAII32 (pH 8.0). Residues 4–28 and 1–26, respectively at pH
2.0 and 8.0, form helices (figures 3.13 and 3.15). At pH 2.0 and 100 ns, the N-terminal
helix formed at 6HDSGYEVHHQKLVFFAED23 contains all the ionisable residues (except
Lys28). By 200 ns, the helix has reduced to 10YEVHHQKLVFF20. Towards the end of the
trajectory at 800 ns, the β-sheet structure increased slightly, accompanied by a decrease
in helical structure. A similar trend was obtained for the peptide at pH 8.0. with the
difference being in the relative percentage of structures sampled as presented in table 3.3.
At pH 5.4 and 7.4, there exist more far-reaching contacts with β-sheets between residues
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1–7 and 11–18 at pH 7.4, and between residues 2–23 and 25–42 at pH 5.4. However, β
content at pH 7.4 is the lowest.
Our observations can be summed up as follows: at high net charge, Aβ42’s N-terminal
segment forms helical structures while a separated C-terminal segment forms β-sheets and
random coil. At physiological pH, β-sheet formation is confined to the N-terminal and
mid-sequence segments, while at the isoelectric pH, all the peptide residues are involved
in β-sheets. For the most part these distinctions remain up to 1000 ns. The structure of
Aβ42 at 7.4 continues to evolve with β-sheet alternatively sampled between the N-terminal
versus mid-sequence segments and the C-terminal versus mid-sequence segments.
The most significant differences in secondary structure involve the sampled coil, β, and
helical structures. The differences are however more poignant when comparing pH 5.4
and 7.4. The latter pH supports a relatively higher coil structure (51%) but lower β-sheet
(15%) contents compared to pH 5.4 (31% coil and 39% β-sheet). The highest content of
random coil structure was observed at pH 7.4 in agreement with the belief that Aβ42 is
unstructured under physiological conditions. The highest percentage of β-sheet was found
at pH 5.4 in agreement with CD results [87]. This result suggests a strong role for pH
conditions in determining Aβ42’s structure. Importantly, it indicates the need for caution
when generalising the results obtained for the peptide under a specific experimental pH
condition. Furthermore, our results revealing Aβ42’s ability to form β-sheet structure
at all four pH conditions, provide an explanation for the observation by Guo et al.[63]
that Aβ is able to polymerise regardless of the charge state. The significant differences
in the extent to which the different structures are sampled, however, suggests possible
differences in aggregation rate, a possible explanation for the role of mutations in AD
pathology. For instance, most of the clinically observed mutations, including Glu22→Gly
(Arctic), Glu22→Gln (Dutch), Glu22→Lys (Italian), and Asp23→Asn (Iowa), lower the
net charge of the peptide and can explain the peptide’s associated enhanced aggregation
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kinetics.
Figure 3.14: DSSP plot showing the secondary structure evolution of Aβ42 monomer under different pH condi-
tions.
Structure (%) pH 2.0 (%) pH 5.4 (%) pH 7.4 (%) pH 8.0 (%)
Coil (14) 29 31 51 38
Beta (0) 29 39 15 21
Bend (7) 11 27 29 20
Turn (19) 10 3 5 8
Helix (64) 21 0 0 14
Table 3.3: The effect of pH on the secondary structure of Aβ42 monomer averaged over the last 500 ns of the
trajectories. The values in parentheses represent the secondary structure at t = 0.
3.5.3 Role of histidine residues
Since the only difference between the Aβ42 models employed in modelling the pH 5.4 and
7.4 is the protonation state of His6, His13 and His14, the differences in the structural
states observed for the two pH conditions may be directly attributed to the protonation
states of the histidine residues. We therefore examined the interactions involving the
three histidine residues for these two pH values. At pH 5.4 and as early as 100 ns the
three histidine residues (and in particular His6) were observed to be involved in extensive
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intermolecular contacts with both the N- and C-terminus of Aβ42. Intermolecular con-
tacts formed by His6 in the early part of the trajectory include residues Asp1, Glu3 and
Ala42. The contact with Ala42 was soon lost, after which His6 employs its protonated
imidazolyl sidechain as a surface promoting intramolecular contact between residues from
different regions of the peptide (figure 3.16). For this to occur His6 adopted an arrange-
ment that allows all interaction surfaces of the imidazole ring to be available. The δ-N
surface forms interaction with residues in the N-terminal segment, while the -N surface
promotes contact with the C-terminal residues. As early as 200 ns 4FR5 and 17LV18 have
begun to adopt β-sheet competent alignment. The underside of the imidazolyl ring forms
a pi-stacking contact with Tyr10, which later recruits 17LVF19. His6 was observed to form
the nucleus of the inter-domain contacts responsible for the higher β-sheet of Aβ42 at pH
5.4 compared with pH 7.4 under which condition the histidine residues were not observed
to serve the described anchoring function.
Instead, at pH 7.4, the N- and C-terminal segments avoid interacting with each other,
Figure 3.15: Aβ42 monomer structures at different pH and time. Histidine and acidic residues are shown in
green and red, respectively, while the KLVFFA sequence is shown in liquorice coloured by atom names. The N-
and C-termini are respectively shown as blue and red beads.
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which is likely a consequence of charge incompatibility between the hydrophobic C-
terminal and the predominantly hydrophilic N-terminal. As can be observed in the dis-
tance maps for pH 7.4 (figure 3.13), Aβ42 exhibit an interaction pattern mostly suggestive
of a disordered state and limited β-sheet formation. The net charge removal when moving
from pH 7.4 (Aβ−342 ) to pH 5.4 (Aβ
0
42) thus promotes hydrophobic interactions between
the different segments, which in turn leads to significant increase in β-sheet formation.
We believe this reduction in electrostatic repulsion between the N- and C-termini to be
an important driving force for the fast aggregation kinetics observed for Aβ under slightly
acidic pH [60–62].
Figure 3.16: The role of His6 in promoting β-sheet in Aβ42 monomer at pH 5.4. Contacts formed by His6
(green), Asp1, Tyr10 and Val24 are shown. The δ and -N atoms of His6 are shown as black and blue beads,
respectively.
3.6 Conclusion
Using explicit solvent MD simulations on the microsecond time-scale and two GROMOS96
force fields, we investigated different influences affecting the secondary structure of the
Aβ peptide. We conducted a comparative study of Aβ40 and Aβ42 and also present a
perspective on the intramolecular effects of the histidine protonation state on Aβ42, ex-
plaining how this leads to the experimentally observed increase in aggregation kinetics at
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acidic pH[60–63]. Our simulation results revealed that both peptides are mainly unstruc-
tured in the first 10 N-terminal residues. However, Aβ40 is more disordered in this region
than Aβ42, which also samples either a pi-helix or β-sheet in the N-terminal residues. The
β-sheet-rich self-recognition motif 16KLVFF20 was sampled in both peptides in our sim-
ulations but to a higher degree in Aβ42. Both force fields reveal a loss of the C-terminal
helix for both peptides, replaced by random coil and β-sheets. We observed the Gly37-
Gly38 hinge structure in Aβ42, which was identified as an important feature distinguishing
Aβ42 from its C-terminal truncated relative[56,57]. To validate the force field models, we
calculated NMR chemical shifts using CamShift [78] and compared them to experimen-
tally determined chemical shifts[65]. For the ffG53a6 simulations of Aβ40 and Aβ42, we
found that the conformational sampling converged to an ensemble that is representative
of the experimental data after 500 ns of simulation time. In addition, only the ffG53a6
suitably capture the rapid structural conversion expected for an intrinsically disordered
peptide like Aβ. The ffG43a2 simulations, on the other hand, fail to completely reproduce
the experimental NMR chemical shifts. The largest deviations were observed for the N-
terminal half of Aβ40 and Aβ42, for which ffG43a2 predicts a rather stable α– and pi-helix,
respectively. The comparison between calculated and experimental chemical shifts allows
us to conclude that in this region, ffG43a2 overestimates the stability of the N-terminal
helix and generally underestimates the conformational flexibility of the Aβ peptides.
We subsequently investigated the effect of pH on the structural dynamics of Aβ42 monomer.
Previous experiment had indicated the structure and aggregation of Aβ are largely af-
fected by pH. For instance by mutating selected residues in Aβ40, a significant correlation
was observed between net molecular charge and aggregation[63], while in the case of Aβ42,
a higher aggregation and toxicity was reported at pH 5.8 than at physiological pH[88].
In our in silico study, we modelled four pH states by selecting the ionisable states of
Aβ42 residues as expected under corresponding pH conditions. Our results show that,
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under extreme pH conditions (pH 2.0 and pH 8.0) Aβ42 structural dynamics suggests a
two-domain interaction system with the highly polar N-terminal domain folded into he-
lices, while the hydrophobic C-terminal segment samples β-sheet and coil structures. At
both the isoelectric (5.4) and physiological (7.4) pH, on the other hand, Aβ42 appears
to be composed of a 3-folding units. At pH 5.4, the N- and the C-terminal domains
cooperatively form an extensive network of β-sheets via His6 with the CHC. The double
protonation of His6, His13 and His14 at this pH reduces the net peptide charge from −3
(pH 7.4) to zero, increasing intramolecular interactions by enhancing hydrophobic con-
tacts. That is, the N-terminal segment becomes better able to interact with the highly
hydrophobic C-terminal segment as a result of a lowering of electrostatic repulsion. The
absence of these factors at pH 7.4, and the two other pH values, explains why Aβ42 forms
significantly high percentage of β-sheet only at the isoelectric pH.
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3.7 Supplementary information
Chemical shift calculation with CamShift
Chemical shifts, conventionally obtained from NMR experiment, are powerful tools for
determining the structure of organic compounds in particular[89,90]. The delicate depen-
dence on the chemical environment, molecular geometry, and chemical bond types make
them highly applicable in biological structure investigation for determining molecular con-
formation. Computational methods are increasingly exploiting this dependence on local
configurational parameters to predict chemical shifts for biomolecular systems. Both ab
initio and semi-empirical quantum chemical calculations have yielded good accuracy in
predicting chemical shifts [91–97]. The high accuracy associated with quantum chemi-
cal approaches notwithstanding, their restriction to systems containing fewer number of
atoms than typically encountered in proteins and nucleic acids precludes them from rou-
tine use in protein structure prediction.
To calculate chemical shifts, CamShift employs the intricate network of contributions
within the 3-dimensional protein structure using a polynomial expansion of the inter-
atomic distances[78]. Equation (3.2) depicts the different contributions used in approxi-
mating the dependence of the chemical shift on local configuration.
δcalci = δ
rc
i + δ
sc
i + δ
bb
i + δ
φ
i + δ
nb
i + δ
RC
i + δ
HB
i + δ
i−1
i + δ
i+1
i (3.2)
The total chemical shift of atom i (δcalci ) involves separate terms representing contributions
from the sidechain atoms (δsci ), backbone atoms (δ
bb
i ), the dihedral angle (δ
φ
i ), nonbonded
interactions (δnbi ), ring current effect (δ
RC
i ), hydrogen bonds (δ
HB
i ), neighbouring atoms
(δi−1i and δ
i+1
i ), while δ
rc
i represents the chemical shift of atom i in random coil confor-
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mation as obtained from NMR database. Equation (3.2) can be re-written as
δcalci = δ
rc
i +
∑
j,k
αj,kd
βj,k
j,k (3.3)
where αj,k and βj,k (the value of which is 1 if covalent bond exists, otherwise 1 and -3) are
parameters determined by the atom and residue under consideration. dj,k is the distance
between atoms j and k. Experimental shifts from NMR database were subsequently
employed for fitting each parameter. Benchmarking calculations using different protein
test sets were reported to generate root mean square deviations from experimental data
(table 3.4 ) that are comparable with the values obtained for SPARTA[97] and ShiftX[94],
two leading chemical shift predictors[78].
Atoms CamShift SPARTA ShiftX
N 3.01 (2.78) 2.87 (2.66) 2.87 (2.66)
HN 0.56 (0.56) 0.58 (0.53) 0.59 (0.55)
HA 0.28 (0.26) 0.30 (0.26) 0.30 (0.28)
Cα 1.30 (1.22) 1.19 (1.03) 1.30 (1.14)
Cβ 1.36 (1.19) 1.30 (1.07) 1.42 (1.25)
C’ 1.38 (1.12) 1.39 (1.05) 1.48 (1.19)
Table 3.4: How RMSδcalc values for CamShift compare with the quantum chemical-based SPARTA[97], and
ShiftX[94]. The predictions employed a test set comprising 28 proteins; the values appearing in parenthesis were
obtained from 7 proteins.
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Chapter 4
Alzheimer’s disease: In search of
treatment
4.1 AD drug discovery and mechanisms of toxicity
Aβ toxicity features a plethora of biochemical process disruption that eventually culmi-
nates in AD. This perhaps can be attributed to the high structural diversity (both the
aggregation and conformational states) of the Aβ peptide. Different Aβ assemblies are
associated with different degrees of cellular toxicities: this suggests the existence of either
toxicity mechanisms varying from one Aβ assembly to the other, or simply a varying
degree of the same toxicity pattern. The exceedingly high structural complexity associ-
ated with Aβ notwithstanding, damage of neuronal and synaptic structures is recognised
as the common significant theme characterising Aβ’s involvement in AD. This results
from a diverse disruptive action of the amyloid peptide on subcellular processes. On cell
membranes and membrane channels electrophysiological studies including the long-term
potentiation (LTP) measurements [98, 99] revealed a Ca2+ (in particular) homeostasis
disruptive effect resulting in increased Ca2+ influx, excitotoxicity and eventually synap-
toneuronal death[100–103]. These effects are mediated both by the structural interaction
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of Aβ with membrane lipids and via the action of Ca2+-, K1+- and glutamate (NMDA)
receptors[100, 104]. Additional mechanisms include induction of oxidative stress and for-
mation of highly toxic radicals, and a caspase-derived apoptotic process which amongst
others result from high Ca2+ influx and mitochondrial destruction[105,106]. The pathol-
ogy of Alzheimer’s disease is characterised by a host of disease influencing factors and
many more underlying biochemical components of the associated neuronal degeneration.
The implication of this is in two respects. First, the complexity of the disease mechanism
implies the possibility of using different pharmacological agents in the management of
the disease. These drugs are typically aimed at correcting defined aspects of the toxicity
complex. While these are currently employed for symptomatic management, the com-
plexity of the pathology implies the likelihood of pharmacotherapy burden on the patient
since different agents are required to manage different aspects of the disease. Secondly it
implies the presence of multiple targets that can be considered in the search for definitive
cure. Drug development efforts are currently being undertaken on two fronts including
the search for biomarkers needed for facilitating early diagnosis, and the search for com-
pounds capable of altering the identified underlying molecular causes of AD.
4.2 Current treatment strategies
For the pharmacological management of AD it is often necessary to make a distinction
between factors immediately responsible for disease signs and symptoms from those ini-
tiating the entire pathology. While the latter represent the ideal in AD management,
the former are currently of crucial immediate importance for initiating treatment plans
that assuages patients discomfort. In this regard, Terry et al. suggested in 1991 that
the degree of synaptic function loss should be considered in staging Alzheimer’s disease
with respect to cognition loss rather than the two accepted hallmarks of the disease, that
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is, senile plaques and neurofibrillary tangles [107]. The cholinergic, glutaminergic and
GABAergic synaptic neuron networks have been observed to be significantly impaired
as a result of the Aβ-induced neurotoxicity[108, 109]. Following the establishment of a
relationship between AD and cholinergic function loss, the cholinergic hypothesis was pro-
posed in the early 1980s[110]. According to the hypothesis, cognitive decline observed in
AD pathology is a consequence of compromised cholinergic neurotransmission in both the
cerebral cortex and the forebrain. This belief then prompted the search for compounds
with cholinesterase-blocking activities to halt the depletion of the CNS levels of acetyl-
choline.
The major factor in the advent of treatment with cholinesterase inhibitors was the post
morterm detection of a significant reduction of the levels of biomarkers associated with
the cholinergic neurons in severe Alzheimer’s disease brains. Clinical trials[111–114] were
conducted starting with the natural anticholinesterase agent physostigmine obtained from
the plant Physostigma venenosum Balf[111]. The initial trials were plagued with signifi-
cant gastrointestinal adverse drug reactions especially in the case of the first-generation
cholinesterase inhibitors, physostigmine and tetrahydroaminoacridine (tacrine), and ad-
ditional hepatic reactions observed in a small number of patients in the case of the second
agent. In 1993, Tacrine became the first drug treatment to be approved by the Food
and Drug Administration (FDA) for the management of Alzheimer’s disease [114–117].
Three second-generation cholinesterase inhibitors are currently approved for the treat-
ment of mild-to-moderate AD, and these are donepezil, galantamine, and rivastigmine.
They all act either as reversible (donepezil, the first drug in this category to be licensed
for use in AD, and galantamine) or pseudoreversible[117] (rivastigmine) inhibitors of
acetylcholinesterase and butyrylcholinesterase (rivastigmine). Huperzine-A is additionally
available for use in China. Memantine, licensed for the treatment of moderate-to-severe
Alzheimer’s disease, regulates the central nervous system’s (CNS) concentration of the
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neurotransmitter glutamate by blocking the NMDA (N-methyl D-aspartic Acid) recep-
tor. The concurrent administration of both memantine and the cholinesterase inhibitors
has increasingly been employed to take advantage of their complementary activities.
The symptomatology of Alzheimer’s disease is composed of both cognitive and noncogni-
tive symptomatic presentations. While the greater percentage of drug trials are directed at
evaluating the efficacy of cholinesterase inhibitors on cognitive presentations, the noncog-
nitive symptoms–especially in the advanced disease–are predominantly responsible for
hospital admissions. Clinical management of the symptoms of Alzheimer’s disease with
the cholinesterase inhibitors and memantine, while it in many cases has modestly im-
proved the quality of life of sufferers, it has conspicuously left the course of the disease
unaffected. Literally, the import of this is that once diagnosed of AD the individual pro-
gresses through phases of progressive cognitive and neurological decline and ultimately
to death with no treatment capable of slowing down, let alone aborting the course. The
past few decades have witnessed increasing research efforts both in the academia and in
the industry specifically focussed on designing definitive therapies capable of modifying
the disease path. Some of such efforts have advanced to preclinical and clinical phases of
testing, of which a significant percentage have failed either as a result of insufficient proof
of efficacy or serious toxicities.
The current search for a definitive treatment of Alzheimer’s disease is principally based on
the amyloid cascade hypothesis and biochemical events secondarily triggered as a result.
Drug development focussing on the Aβ-centric pathway maybe broadly categorised into
compounds directed at:
1. Aβ peptide production from APP
2. Aβ misfolding and aggregation
3. Aβ clearance.
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The first two points are discussed in detail.
4.2.1 Aβ peptide production from APP
The enzymatic cleavage of the amyloid precursor peptide into Aβ is widely accepted as
the foremost step in the subsequent neurotoxicity complex that characterises Alzheimer’s
disease and designing drug candidates that target this step has all along constituted a vi-
able drug design approach. The β–secretase which cleaves the N-terminal segment of Aβ
and the γ-secretase that cleaves APP at Aβ’s C-terminal segment thus represent an at-
tractive target for drug design. As a further indication of the flurry of interest in this drug
design school of thought, the past few decades have witnessed significant research efforts
involving both academia and pharmaceutical industries out of which some inhibitors have
reportedly been identified with inhibitory activities[118–124]. Targeting the secretases in
developing Alzheimer’s disease treatment is however not without serious drawbacks. In
the first instance, there are strong indications that both enzymes are involved in other
biological processes making the business of inhibiting the secretases a very tricky one.
Apart from APP cleavage, the enzymatic activity of the γ–secretase, for example, also
includes the transmembrane Notch growth hormone receptor, the voltage-gated Na chan-
nels, the vascular endothelial growth factor (VEGF), the CD44, and a number of other
endogeneous substrates[125–129]. Inhibiting γ–secretase thus carries the potential risk of
disrupting important biological functions. In the case of β-secretase, the solved structure
of the enzyme revealed an extensive binding site that in practical terms precludes the de-
sign of small-molecule non-peptidic inhibitors capable of disrupting the APP-processing
function of the enzyme[130]. This however did not completely discourage search into
prospective BACE-1 inhibitors, some of which reportedly inhibit APP processing in ani-
mal models[131,132].
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4.2.2 Aβ aggregation inhibitors
Alzheimer’s disease pathology of synaptoneuronal loss is characterised by the presence
of amyloid plaque (mostly extracellular) and neurofibrillary tangles (intra-axonal) in the
brain of the sufferers of the disease. Of the two causative peptides, Aβ currently takes
the centre stage in research spending, both facilitated by and resulting in the availabil-
ity of a large body of data correlating structural features (e.g., the formation of soluble
oligomer) with neurotoxicity. The Aβ composite conformational system is characterised
by the presence of a dynamic structural equilibrium between the different aggregation
states of the peptide consisting of monomers, soluble oligomeric intermediates and the
insoluble fibrils[133,134]. While the specific details of the structural events accompanying
the conversion from the intrinsically disordered monomer to the β-sheet-dominated higher
order aggregates remain unclear, there are evidences that the neurotoxicity cascade char-
acterising AD is linked to the formation of soluble Aβ oligomers[135]. This however does
not singularly attribute neurotoxicity to β-sheet formation alone, otherwise the original
amyloid hypothesis identifying the high-β-sheet-containing fibrils as the basic neurotoxic
unit in AD would have not required revision. Instead, AD neurotoxicity appears to result
from a highly complex interplay between Aβ solubility, β-sheet content, peptide sequence,
as well as prevailing factors in the local brain environment.
The paucity of knowledge on the aggregation pathway notwithstanding, the misfolding
and aggregation of Aβ peptides provide a viable mechanism being explored in AD drug
discovery [136] In principle, the gamut of molecular events surrounding the Aβ peptide’s
involvement in Alzheimer’s disease present possible targets that may be considered for
treatment. And the conformational aspects of the peptide have been extensively ex-
plored[137, 138]. Such efforts have included the in vitro screening of large chemical li-
braries [139], an approach traditionally employed in pharmaceutical industries which has
the benefit of generating viable hits with desirable physicochemical properties. This ap-
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proach successfully identified small molecule aggregation inhibitors belonging to different
chemical classes including curcumin[140], melatonin[141], tannic acid [142], trehalose[143],
nicotine[65], and dapsone[144], to mention a few. While the small size of this category of
chemical compounds make them ideal for optimisation, this feature at the same time is
what disqualifies most of them from progressing beyond the initial in vitro studies onto
clinical testings. This largely results from the absence of binding specificity, a challenge
further attributed to the fact that the Aβ peptide systems represents a structurally ill-
defined target, with such dynamic conformational aspects and polymorphism that it is
practically impossible for such small molecules to effectively arrest aggregation.
One approach that circumvents the challenge with small molecular inhibitors is the im-
munotherapeutic method employing both active and passive immunisation for clearing
endogenous Aβ [45, 145]. In active immunisation sequence fragments of the Aβ peptide
are injected into subjects to stimulate antibody production, while passive immunization
involves the injection of prepared anti-Aβ antibodies [45,145]. Immunotherapy eliminates
the size-dependent lack of binding specificity associated with small molecule drugs. And
both cognition and plaque deposition were reported to be improved in trials involving
APP transgenic mouse models. Plaque clearance, however, appeared to be significantly
compensated for in the brain by a tripling and quadrupling of the quantity of cerebral
amyloid vascular deposits[146]. Occurrence of microhaemorrhages in a small but sig-
nificant amount of human subjects subsequently led to the stoppage of clinical testing.
However, reports emerging from a subset of treated patients strongly suggest a relative
improvement of the cognitive decline profile[147,148].
Lastly, an entirely different AD drug discovery philosophy known as the rational drug
discovery approach, makes use of insight into Aβ’s structure and aggregation dynamics in
the design of aggregation inhibitors. At the most fundamental level, this approach utilizes
knowledge of the identified critical folding (Aβ being a disordered peptide cannot be said
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to form a unique 3D structure) units of the monomers which, importantly, are also critical
for oligomeric assembly. The various research efforts in this area are discussed under the
following subcategories that should not taken as illustrative and not as an exhaustive
treatment of the topic.
The Aβ self-recognition unit: sequence
The self-recognition unit in the Aβ peptide is made up of the CHC residues 16KLVFF20
which is crucial in the amyloid misfolding event and believed to kick-start the entire
aggregation-dependent neuropathology[138]. The first attempt to target the self-recognition
unit was by Tjernberg et al in a report published in 1996 [76]. This pioneering work paved
way to subsequent designs employing variants of this approach to design aggregation in-
hibitors, also known as β breakers. In the work by Tjerberg et al., the self-aggregating
self-recognition unit was synthesized as part of a peptide that was demonstrated to in-
hibit fibrillation of the full peptide. Expectedly, the strong aggregation propensity of
this peptide coupled with its susceptibility to peptidase degradation prevented it from
being considered for further development. However, this work served to demonstrate the
viability of pursuing this mechanism in the search for amyloid aggregation inhibitors.
In addition, a small number of peptide-based inhibitors were also reported, where the
proposed mechanism of action is the stabilization of the peptide in a helical conforma-
tion via binding to residues 13–23, which includes the self-recognition unit [149]. These
compounds were reported to frustrate assembly into neurotoxic aggregates of the amyloid
peptide[149].
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The Aβ self-recognition: hydrophobicity
Since the high intrinsic hydrophobicity of the Aβ peptide is an important factor in driving
the undesirable aggregation, it was hypothesized that by attaching a charged unit to the
self-recognition unit, the effective hydrophobicity of the self-recognition unit could be
reduced. The self-recognition unit provided a good template for in this instance, mostly
because of its critical role as the recognition element in fibril assembly[150, 151]. To
confirm this hypothesis, Ghanta et al. incorporated a poly-K(i.e, polylysine) fragment to
the C-terminus of Aβ 15−25, resulting in significant reduction in Aβ 39’s amyloidogenic
properties [150]. Inhibitors with poly-K units inserted via the N-terminus of the self-
recognition unit were reported to be ineffective or mildly amyloidogenicity enhancing. In
addition to this outcome, in 1999, Pallitto et al. published their findings on the activities
of hybrid peptides containing poly-K units at the C-termini of a number of short self-
recognition unit-containing Aβ peptides[152]. They observed that the hybrid peptide’s
effect on Aβ’s toxicity and aggregation profile are related. Interestingly, however, these
compounds also significantly increased Aβ’s aggregation kinetics leading to the suggestion
that the observed lowering of Aβ toxicity might have resulted from a facilitated conversion
of toxic Aβ oligomers into relatively less toxic fibrils. In these studies, however, a minimum
of three lysine residues were required for the observed anti-amyloid activities.
The Aβ self-recognition: disruption of amyloid binding pattern
Another way to disrupt the amyloid aggregation process of the self-recognition unit is by
incorporating bulky groups capable of sterically interfering with intermolecular contacts
necessary for cross-β structure formation. Findeis et al. in 1999, designed a range of
hybrid aggregation inhibitors incorporating the bulky cholic acid at the N-terminus of
the CHC peptide LVFFA. In vitro assays revealed marked lowering of Aβ40 and Aβ42’s
aggregation and toxicity [153, 154]. However, administration of the inhibitors to rats
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revealed significant hepatic clearance, which effect was pronounced in inhibitors with L-
amino acids. The D-analogues were observed to possess higher hepatic stability [153,154].
Another bulky group that has been used involves the methylation of the amide N on al-
ternate residues of Aβ peptide fragments which both inhibited fibril formation as well as
dissolved mature fibrils [155,156]. The incorporation of the amino acid proline within the
self-recognition unit sequence was also shown to produce inhibitors capable of interfering
with Aβ fibrillization [157]. Since both N-methylation and proline lack the amide N,
they most likely produce the observed inhibitory effect via a disruption of intermolecular
hydrogen bonds.
The Aβ self-recognition: stereochemistry
As promising as these peptide-based molecules are, they generally suffer from a drawback
relating to their rapid clearance from the circulation, especially by endogenous peptidases.
This drawback is partly mitigated by the incorporation of bulky non-peptide groups in
the peptides; by doing so this confers on the inhibitors a measure of resistance to pro-
tease activities. A second approach employs inhibitors based on D-enantiomeric amino
acid residues. Certain D-Peptides have been found to inhibit both Aβ aggregation and
neurotoxicity [158–164]. These include D-peptide sequences constructed based on the key
amyloidogenic motif (the self-recognition unit), 16KLVFFA21, which in addition to the
desired fibril-disrupting abilities and protease-resistance, also exhibit little to no immuno-
genicity compared with the L-peptide-based counterparts [161]. This is the approach
being pursued in the present work, and the design aim is to realise aggregation inhibitory
effects, protease resistance, as well as an non-immunogenicity in the same compounds.
Some years ago, a 12-residue D-peptide, code-named D3, and with the sequence Arg-Pro-
Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg, was designed using mirror-image phage dis-
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play selection in the group of Prof. Dieter Willbold, the head of the Institute of Complex
Systems 6, Forschungszentrum Ju¨lich [162]. The peptide demonstrated amyloid aggrega-
tion inhibitory effect, a dose-dependent reduction in plaque load, as well as improvement in
cognitive function in transgenic mice [162,163]. Rather than merely disassemble preformed
fibrils, the peptide is believed to drive the aggregation path through a nontoxic pathway
in which D3 precipitates the formation of nontoxic amorphous Thioflavin-negative aggre-
gates [162].
4.3 Aggregation inhibition with D3
In mirror-image phage display, a technique described by Mayr et al., the target protein is
converted into its D-enantiomer via chemical synthesis followed by phage libraries screen-
ing for strongly binding L-peptide ligands [165]. Synthesis of the D-enantiomeric form of
the selected ligands should then produce D-peptide ligands with desirable binding proper-
ties for the original target L-protein. The D3 peptide was discovered in a similar fashion
[162]. Using highly dilute solutions of synthetic D-Aβ42 (2 nM under which solution con-
dition low order Aβ42 assemblies are expected to exist) as target protein, an entire phage
library of more than one trillion 12-residue peptides was screened for high-binding ligands,
a biopanning process that was conducted six times thereby enriching the phage. Sequence
determination of the predominant peptide in the enriched phage identified D3 as consti-
tuting about 40% of randomly selected phage peptides, with the remaining high-affinity
ligands displaying greater than 75% sequence identity to D3[163].
Both in vitro and in vivo experiments were performed to determine the effect of D3
on Aβ42 aggregation and toxicity. In vitro determination of amyloidogenic properties of
amyloid proteins in most cases utilises Thioflavin T (Tht) fluorescence assay in which amy-
loid property is determined by the characteristic fluorescence enhancement and red shift
exhibited by Thioflavin T, the chloride of 4-(3,6-dimethyl-1,3-benzothiazol-3-ium-2-yl)-
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N,N-dimethylaniline, upon binding to ordered β-sheet-rich amyloid structures [166–168].
In addition, an apple-green birefringence upon staining a peptide system with Congo Red
(Sodium 3,3’-([1,1’-biphenyl]-4,4’-diyl)bis(4-aminonaphthalene-1-sulfonate) is also indica-
tive of amyloid properties. Both ThT and Congo Red assays revealed significant and
concentration-dependent reduction in Aβ amyloidogenic properties when treated with D3
[162,163].
Following treatment with D3 using both the oral and direct hippocampal administration
routes, transgenic mice expressing human APP and presenilin-1 genes were reported to
show significant improvement in cognition over the untreated group as determined by
the Morris water maze experiment. Histological assessment using the frontal cortical and
hippocampal brain sections further revealed significant reduction in both plaque load and
plaque-dependent inflammation in the treatment group [164]. Follow-up measurements
aimed at determining the possible mechanisms of D3/Aβ aggregation inhibition included
Aβ particle size determination by dynamic light scattering (DLS). These experiments re-
vealed an increased average particle size in Aβ42 solution systems from amyloidogenic 300
A˚ hydrodynamic radius (without D3) to large amorphous aggregates of about 800–7000 A˚
hydrodynamic radius (with D3) that were both ThT- and Congo Red-negative. This re-
sult was further confirmed by electron microscopy (EM). In other words, treatment with
D3 peptide abolishes Aβ toxicity and converts the neurotoxic water-soluble oligomers
into non-toxic, non-amyloidogenic and non-fibrillar aggregates but without increasing the
concentration of Aβ monomer.
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Chapter 5
Computational study of D3’s
anti-amyloid properties
5.1 Overview
The simulations performed in this section rest on the background of insight obtained from
the conformational study of Aβ discussed in chapter 2.
A general outline of the study plan is first presented here. The overarching aim of the
studies conducted in this section is to unravel the mode of action. Two aspects of the
D-peptide’s inhibitory activities are important: D3 binding and binding efficacy. Inves-
tigation into the strength and specific nature of the Aβ/D3 binding requires identifying
residues within both peptides that are responsible for the interaction. Here, a global
optimisation method implemented in the GMIN programme [169]. turned out to be par-
ticularly useful in this respect because it allows for the generation and optimisation of
protein complexes, taking into account translational, rotational and conformational de-
grees of freedom (flexible docking). The methodology description below includes a detailed
introduction to the GMIN simulations. The optimised Aβ-D3 complexes were subjected
to a rigorous scoring, in which the binding energy for each complex was computed, and
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then ranked. The most favourable complexes based on binding energy were selected for
further processing using explicit solvent MD.
The term binding efficacy, used as a general analogy to pharmacological efficacy, describes
the effect of D3 binding on Aβ. In order to have an idea of how well the calculations agree
with experimental measurements, changes in secondary structure upon D3 binding have
been monitored. This makes it possible to take the description of binding event beyond
mere binding to what may be described as effective binding. This becomes particularly
useful in the section dealing with the investigation of different lengths of a close relative of
D3 where strong binding was observed to not automatically translate to efficacy. We have
employed explicit solvent MD simulations together with appropriate control systems to
quantify the effect of binding on Aβ. The applicability of explicit solvent MD is however
not limited to quantifying efficacy, it is also used for decomposing the interaction energy
into residue–residue contributions. The resulting energy matrix provides an indication
of the stability of the system, and more importantly of the relative significance of the
individual residues in driving the inhibitor-Aβ peptide interactions.
5.2 Methodology
5.2.1 Peptide models
D3 peptide
D3 is a twelve-residue peptide with the sequence 1RPRTRLHTHRNR10 containing all
amino acid residues in the D-enantiomeric configuration. To obtain suitable GROMOS53a6
[9] and CHARMM22 [170] force field models, for each residue the chirality of the backbone
centred around the Cα atoms was inverted in congruence with each force fields topological
convention. In GROMOS53a6 this entailed inverting the order for the improper dihedral
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entry from ”CA N C CB” for L-amino acids to ”CB N C CA” for the D-enantiomer. In
CHARMM22 it was required to invert the sign for the improper dihedral angle formed
by ”N C CA HA” from −117◦ to +117◦. New D-amino acid entries were thus created
in both force field for all twenty amino acid residues using new residue names essentially
involving prefixing the old names with a ”D” and dropping the last letter. For instance,
D-leucine has the name ”DLE” in our model.
Starting with a fully extended peptide configuration for D3 generated with the CHARMM
simulation package [171], the conformational space of the peptide was studied in a 100
ns-MD simulation conducted with GROMACS [83] using the ffG53a6 force field [9]. The
extended peptide was first subjected to a cycle of in vacuo steepest descent minimiza-
tion and then inserted in a cubic water box (SPC water model) using a 10 A˚ separation
distance from the peptide to the box edges. Boundary treatment involves surrounding
the simulation box with its periodic images (i.e., periodic boundary condition). A 14 A˚
cutoff was used in truncating short-range forces, while the long-range component of the
Coulombic forces was treated using the particle mesh Ewald method. Sufficient numbers
of Na+ and Cl− were included to neutralise the net +5 peptide charge emanating from
the five arginine residues and at the same time to achieve a 150 mM NaCl concentration.
After further minimisation steps involving steepest descent followed by conjugate gradi-
ent minimisation, an equilibration dynamics in the NPT (24833 atoms, 1 atm, 300K)
ensemble was performed using a 239 kcal/mol restraining force on peptide heavy atoms.
This lasted 1 ns, and it served to relax the water molecules around the peptide in order
to remove high forces resulting from atomic clashes while at the same time removing
pockets of empty space resulting from the random process by which the water molecules
were added to the box. After the position restraints were turned off, a 100 ns production
MD run was performed under simulation conditions essentially the same as in the equi-
libration step, except that a Nose´-Hoover thermostat was used instead of a Berendsen
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thermostat. In addition pressure coupling made use of the Parrinello-Rahman barostat
in place of the Berendsen barostat. The neighbour list was updated every 10 ps while
new coordinates and energies were saved every 20 ps. The resulting trajectory, containing
Figure 5.1: Most populated D3 structure.
5000 configurations, was subjected to cluster analysis using a 20 A˚ RMSD cut-off. The
largest cluster, for which a representative configuration is shown in figure 5.1, features
an extended structure. The adopted conformation of D3 is driven by an effort to min-
imise electrostatic repulsion, which requires a careful spatial arrangement of the sidechain
groups. This is however not unexpected, especially given that the peptide contains no
more than twelve residues out of which five are positively charged. The central struc-
ture of the largest cluster (figure 5.1) was employed for all subsequent interaction studies
involving Aβ peptides and is hereafter referred to as ”D3” peptide.
Aβ monomer
The five largest cluster centres obtained from the 1.5 µs MD simulation of Aβ42 (force field
ffG53a6) were independently used as the starting structure for studying the interaction
of D3 with Aβ42 monomer. The choice of five conformationally different Aβ structures
(figure 3.8) ensures structural variability to account for the structural flexibility of the
peptide in solution. This helps to limit the error of conformationally biasing the binding
had a single conformation been employed for Aβ42. In addition, the five cluster centres
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were obtained from the equilibrated part of the trajectory as determined by experimental
chemical shift validation.
Aβ pentamer
The coordinate file PDB 2BEG of an Aβ42 pentamer solved by solid state NMR was
taken from the www.rcsb.org database [172]. The structure resulted from solid-state NMR
investigation of Aβ42 fibril which suggested the pentamer as the β-sheet structural unit of
the fibril. In this structure, Aβ42 samples a strand-turn-strand conformation with residues
18–26 and 31–42 forming an in-register β-sheets. The N-terminal residues 1–17 were,
however, disordered and lacked coordinates. Starting from 2BEG, residues 1–17 taken
from the Aβ42 monomer MD simulation and sampling a coil conformation were stitched
onto each of the five peptide units composing the pentamer. A coil conformation was
decided for the attached N-terminal residues 1–17 based on the experimental observation
that this section of the peptide is disordered [172]. Furthermore, the generated structural
construct was thereafter subjected to global optimisation with basin-hopping in which the
positions of residues 18–42 were fixed while the added residues 1-17 of each peptide were
perturbed until all atomic clashes were resolved and a low-energy structure was obtained.
Several cycles of basin-hopping were conducted before a sufficiently disordered N-terminus
was obtained in each of the five chains. This also necessitated the alternate freezing of
the peptide chains. For example, the freezing of the coordinates of chains 1, 3 and 5
allowed chains 2 and 4 to be perturbed until they were adequately separated from the
frozen chains. Then chains 2 and 4 were frozen while chains 1, 3, and 5 were perturbed.
This was repeated until the total energy of the entire system converged. Thereafter, 500
ns explicit solvent MD using ffG53a6 was performed on the full-length Aβ pentamer at
300 K and 350 K. The simulations were performed in the absence of any form of restraint
so as to determine whether or not the new model would remain stable. The full-length
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pentamer remained stable at both temperatures. A clustering analysis with a 1 A˚ RMSD
cut-off was subsequently performed on the MD trajectory at 350 K using the Cα atoms
of residues 18–42 of each peptide for least squares fitting. The representative structure
of the most populated cluster, hereafter referred to as Aβ pentamer or simply pentamer,
is shown in figure 5.2. This structure was then selected as the starting structure for the
Aβ42 pentamer-D3 interaction studies using GMIN [169].
Figure 5.2: Full-length Aβ42 pentamer in VMD green NewCartoon representation showing the top view (a) and
the sideview (b). The sidechain groups of the charged amino acid residues are represented with liquorice coloured
according to charges–red and blue respectively for acidic and basic amino acid residues. The newly modelled
residues 1–17 sample a disordered state and the fibril-stabilising salt bridges involving Asp23 and Lys28 are visible
in (b) while Glu22 lies above the fibril plane.
5.2.2 Generation and optimisation of Aβ complexed with D3
Basin-hopping (BH) simulations
The basin-hopping (BH) approach to global optimization [174,175] is equivalent, in prin-
ciple, to the Monte Carlo-minimization method [173]. It involves proposing moves by
perturbing the current geometry, which are either accepted or rejected depending on the
difference between the energy of the local minimum of the instantaneous configuration
following energy minimisation, and the energy of the previous local minimum in the chain.
What results in essence is that the typically complex potential energy surface (PES) is
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transformed into what has been referred to as the basins of attraction [174, 175] consist-
ing of all the local energy minima. That is, the energy for configuration R can now be
expressed as,
E˜(R) = min{E(R)} (5.1)
where min signifies energy minimisation. With the transformed energy surface, it becomes
feasible to take large steps, especially since the aim is to step between the energy minima
in search of the global configuration. In addition, the need to maintain detailed balance
while taking the steps between the minima vanishes since the BH method is intended for
locating the global minimum, and not for sampling thermodynamic properties. The BH
algorithm has been implemented in the GMIN program [169] employed in the present work
for finding the global minimum of D-peptide-Aβ complexes. In all the interaction studies
performed using GMIN, the Aβ peptide(s) represent the receptor molecule(s) whose co-
ordinates were fixed while the D-peptides represent the ligand molecules.
Aβ monomer/D3
With the aid of the oligomer-generation procedure [176] implemented into GMIN, 1000
Aβ42-D3 binary complexes were generated for each of the five Aβ42 starting structures,
i.e. a total of 5000 Aβ42-D3 complexes. The structure of D3 was taken from a 100 ns
explicit solvent MD simulation described above. The C-terminus was amidated to mimic
the employed experimental condition in which D3’s C-terminus was attached to a surface
(personal communication with Prof Dr. D. Willbold).
The generated complexes were subsequently optimized using 300 BH steps in which di-
hedral angle moves [177], small rigid body rotations and translations [178] were applied
to D3 peptide. This involves a twisting of the dihedral angles to a maximum of 30 ◦ with
a 30% twisting probability while the rigid body rotation and translation were performed,
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respectively, to a maximum of 80◦ and 2 A˚. Parameters from the CHARMM22 force field
were employed for treating interacting systems [170], while the generalised Born solvent
model FACTS [179]was used in modelling the aqueous environment. The reason for using
the CHARMM force field for the GMIN simulations, rather than the GROMOS force field
employed in the MD runs, was because the latter force fields are yet to be interfaced to the
GMIN programme. In addition, the CHARMM force fields had not yet been implemented
in GROMACS at the time of commencement of the study.
A total of 5000 Aβ42 monomer-D3 compplexes were generated and optimised, after which
the binding energies (∆∆Gbind, section 5.2.3) were calculated and used in ranking the
predicted complexes. The top-ranking 100 complexes were subsequently submitted to
explicit solvent MD simulations described below.
Aβ pentamer/D3
A protocol similar to that described for the Aβ42 monomer-D3 system was employed for
the study of the full-length Aβ42 pentamer complexed with D3 (stoichiometry Aβ42:D3
= 5:1). The employed simulation parameters were also similar, except few changes were
necessary to account for the bigger size of the system. To this end, a total of 400 BH steps
were performed. Rigid body rotation (up to a maximum of 90◦) and translation (up to a
maximum of 2 A˚) were applied to D3 only at every BH step. In addition, D3’s dihedral
angles were also twisted with a probability of 30% up to a maximum of 30◦. A total of
4000 Aβ42 pentamer-D3 complexes were generated and optimised. The predictions were
subsequently ranked according to ∆∆Gbind (calculated as described in section 5.2.3). The
100 predictions with the best ∆∆Gbind values were then selected for explicit solvent MD
simulation.
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5.2.3 Calculation of binding energies
To estimate the binding energy (∆∆Gbind), the idea of the MM/GBSA formalism was
employed with force field parameters derived from the CHARMM22 potentials, and the
FACTS implicit solvent parameters employed for the GBSA part:
∆∆Gbind = ∆∆Gint + ∆∆GSol (5.2)
The ∆∆Gbind was calculated as a sum of contributions from interpeptide interactions
and solvation terms. The interaction energy includes van der Waals and electrostatic
interactions between Aβ and D3, while the solvation term contains the polar (electrostatic)
and nonpolar solvation terms:
∆Gint = ∆G
vdw
int + ∆G
ele
int (5.3)
∆∆GSol = ∆∆G
pol
Sol + ∆∆G
npol
Sol (5.4)
∆∆GpolSol and ∆∆G
npol
Sol were each computed by removing the individual terms for Aβ42
and D3 from the energies of the complex:
∆∆GpolSol = ∆G
pol
AB/D3 −∆GpolAB −∆GpolD3 (5.5)
∆∆GnpolSol = ∆G
npol
AB/D3 −∆GnpolAB −∆GnpolD3 (5.6)
∆∆Gbind was computed for each of the optimised 5000 Aβ monomer-D3 complexes and
4000 Aβ pentamer/D3 complexes, and the obtained data used in ranking the predictions.
The top one hundred with the most favourable energies ∆∆Gbind were selected for explicit
solvent MD simulation as discussed below. Within MM/GBSA, ∆∆Gbind is commonly
referred to as the binding free energy, which use has also been largely adopted in this
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thesis. However, it is important to point out that only ∆∆GSol is a free energy, whereas
∆∆Gint is a potential energy (also in MM/GBSA).
5.2.4 Explicit solvent MD
The final explicit solvent molecular dynamics simulations performed with the GMIN-
predicted Aβ-D3 complexes serve different purposes. The first is confirming the stability
of the bound configurations, which is tested by calculating the backbone RMS displace-
ment from the starting (GMIN) structure. The MD trajectory also provides a means of
obtaining a time-averaged description for the energetics of the bound systems. Lastly,
it enables the assessment of the effect of binding (i.e., the binding efficacy) on peptide
structural features. Two groups of MD simulations were conducted: simulations of Aβ-D3
complexes and control simulations of Aβ alone. All MD simulations were performed with
the SPC water model, employing the ffG53a6 force field and a protocol similar to the one
described for D3 conformational sampling above in section 5.2.1. In the simulations of Aβ
monomer-D3, each of the 100 GMIN-generated configurations with the lowest ∆∆Gbind
values was subjected to a 10 ns MD run. With respect to the Aβ pentamer-D3 systems,
the 100 best ∆∆Gbind configurations were first parsed through a clustering procedure to
reduce the geometric redundancies, as D3 binds more specifically to the ordered pentamer
structure than the flexible monomer Aβ. As an example, there are a number of Aβ-D3
complexes in which D3 binds to similar sites in the disordered N-terminal section of the
pentamer. The cluster analysis involves a least-square fitting to the Aβ42 pentamer atoms
and a clustering of D3 placements around the pentamer. The choice of a 2.19 A˚ RMSD
cutoff distance yielded 15 clusters in which redundancies in D3 binding to Aβ pentamer
were largely eliminated. 50 ns MD simulation was initially performed on one the cluster
centres after which this was extended to 100 ns. After it was observed that extending the
simulation to 100 ns did not grant additional information, 5 other cluster centres were
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each subjected to 50 ns MD simulation.
The second set of MD simulations are control simulations of Aβ peptides in the absence of
D3. This, in the case of Aβ monomer, entails independently performing a hundred 10 ns
MD simulations. The starting structures employed were obtained by stripping each Aβ42
monomer-D3 complex off its D3 binding partner. The unbound Aβ were then subjected
to explicit solvent MD simulation following the setup described in section 2. In the case of
Aβ42 pentamer, a single control MD simulation (50 ns) the Aβ pentamer (figure 5.2) was
performed. This was deemed sufficient because the same starting structure was employed
for generating the 4000 Aβ42 pentamer-D3 complexes.
5.3 Results and discussion
5.3.1 Aβ42 monomer/D3
Before discussing the results obtained for the Aβ42 monomer-D3 complexes it is useful
to note that the choice of five different Aβ42 configurations for the global optimisation
was a necessary attempt to capture the high conformational flexibility exhibited by Aβ42
monomer as discussed in chapter 2. Unlike most folded peptides whose conformational
space may be represented by an average structure with essentially invariable backbone
architecture, the Aβ42 monomer conformational space is characterised by its ability to
rapidly interconvert between different secondary structures. This property is factored
into the present setup by employing five different representative structures (cluster cen-
tres). The employment of a single D3 configuration is deemed sufficient since all sampled
states principally consisted of extended conformations driven by the need to increase the
distance between the five arginine residues and thereby minimising electrostatic repulsion.
Finally, the choice of one hundred binding poses for more detailed analysis serves to mimic
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experimental situations where thousands of molecules are involved in peptide-peptide as-
sociation. Ideally, the entire set comprising 5000 D3-Aβ42 binary complexes obtained from
GMIN should have been subjected to MD. This however, would have increased the re-
quired computational time and resources by almost two orders of magnitude. The choice
of 100 poses therefore reflects a compromise between the computational resources avail-
able for this project (provided by the Ju¨lich Supercomputing Centre, Forschungszentrum
Ju¨lich) and the requirement to make the analyses as descriptive (and predictive) of ex-
perimental observations as possible.
The top one hundred favourable ∆∆Gbind values range from−170.75 kcal/mol to−120.05
∆∆Gbind (kcal/mol)
-170.75 -140.83 -132.94 -129.22 -123.01
-170.66 -140.23 -132.65 -128.84 -122.96
-170.17 -139.82 -132.53 -128.58 -122.75
-168.53 -139.63 -132.01 -128.07 -122.54
-161.31 -139.28 -131.72 -128.05 -122.42
-161.20 -138.83 -131.46 -127.05 -122.30
-160.58 -138.78 -131.34 -127.02 -122.22
-154.59 -138.34 -131.25 -126.72 -122.21
-153.43 -138.30 -131.14 -126.45 -122.20
-151.41 -137.87 -131.14 -126.02 -121.99
-146.58 -137.40 -131.04 -125.51 -121.86
-146.11 -136.71 -130.91 -125.29 -121.78
-145.95 -136.37 -130.89 -125.10 -121.48
-145.90 -135.70 -130.65 -124.74 -121.43
-144.68 -135.27 -130.52 -124.36 -120.93
-144.47 -135.00 -130.42 -124.21 -120.89
-144.43 -134.86 -130.04 -123.65 -120.86
-143.49 -133.98 -129.80 -123.45 -120.63
-142.14 -133.67 -129.52 -123.33 -120.08
-141.17 -133.47 -129.44 -123.03 -120.05
Table 5.1: Binding energies (kcal/mol) of the one hundred Aβ monomer-D3 complexes with the lowest ∆∆Gbind.
kcal/mol with an average of −133.87 kcal/mol. The full list has been presented in table
5.1. These were each subjected to 10 ns of MD simulation, making an aggregate of 1 µs
MD simulation. For each of the MD simulations, the minimum separation between Aβ42
and D3 was calculated over the 10 ns MD trajectories and then averaged over the one
hundred systems. This serves as a check to verify the overall stability of the predicted
complexes, and if the switch from implicit solvent in the GMIN simulations to explicit
solvent in the MD simulations has any significant effect on the stability of the systems.
The obtained distance profile in figure 5.3 shows that the average separation distance
stays between 2.8 A˚ and 3.0 A˚ throughout the trajectories. Thus the two peptides remain
tightly bound. The slight fluctuation observed might have resulted from the system’s re-
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sponse to the space-filling effect of the explicit water and the peptides’ thermal vibrations
within the allowed limits of the bound systems. In any case, the magnitude of the fluctu-
ation is sufficiently small to render it incapable of disrupting the tight binding between
the peptides.
Figure 5.4 shows the residue-residue contributions to ∆Gint generated from the se-
Figure 5.3: Average minimum separation between D3 and Aβ42 as a function of time in the 100 Aβ42 monomer-
D3 complexes.
lected 100 binding configurations. Each of the selected Aβ42-D3 complexes had been
subjected to MD simulation and from each resulting trajectory energy the residue(Aβ42)-
residue(D3) interaction energy ∆Gint composed of the nonbonded energies (Lennard-Jones
and Coulombic) was calculated. This resulted in 540 time-averaged energy values for each
binding pose (i.e., 42 x 12). Subsequently an averaging over the one hundred binding poses
was performed to produce the energy matrix shown in figure 5.4. In figure 5.4 the interac-
tion energy map summarises the energetic contributions showing the relative significance
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Figure 5.4: D3-Aβ42 monomer explicit solvent molecular dynamics-generated interaction energies decomposed
into residue-residue interactions. The interaction map represents a mean over one hundred such maps separately
calculated for each unique D3-Aβ42 GMIN-predicted binding poses with the best ∆∆Gbind. The map reveals
residues of the D-peptide preferentially interacting Aβ hydrophilic residues in sequence regions 3 to 11 and 22 to
23 while the two hydrophobic stretches–the CHC and the C-terminal hydrophobic resides–are avoided.
of each residue pair interaction to the association event. The pattern shows D3 as near
exclusively interacting with the N-terminal residues of Aβ42, in particular Glu3, Asp7,
Glu11, Glu22, Asp23. The fact that these five Aβ42 residues are all negatively charged
suggests that interaction with D3 is mediated by electrostatic attraction involving D3’s
five arginine residues. The averaged interaction energies between D3 and Aβ42’s neg-
atively charged residues range between −0.78 to −1.13 kcal/mol, in sharply contrasts
with the −0.09 to −0.20 kcal/mol for Aβ residues in the CHC (residues 13 to 21) and
the C-terminal hydrophobic (residues 25 to 42) sequences. The pattern reveals that D3
preferentially binds Aβ42 monomer’s N-terminal segment. D3 on the other hand shows
little residual selectivity for its interaction with the amyloid peptide. With averaged in-
teraction energies ranging from −0.35 to −0.46 kcal/mol, the five arginine residues shows
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a similar preference for interaction with Aβ monomer which suggests that the reported
amyloid inhibitory activity of D3 involves an electrostatic steering that directs D3 to the
N-terminal half of Aβ. Interestingly the C-terminal end of D3, made of the sequence
HRNR, demonstrates a mildly superior average ∆Gint in partial agreement with the work
of Ghanta et al. [150, 152]. Figure 5.4 shows that D3 binding to the negative residues
in Aβ brings D3 to Aβ’s self-recognition sequence, which is expected to significantly af-
fect amyloid aggregation. This can also be seen in figure 5.5 presenting ten complexes
Figure 5.5: VMD rendenring of some of the one hundred studied Aβ42 monomer-D3 complexes. D3 is shown
as green tube with the sidechain group of arginine residue shown in liquorice. Aβ42 monomer is rendered using a
surface representation coloured according to residue types–red, blue and silver respectively for acidic, basic and
uncharged residues.
randomly selected from the 100 investigated systems. It therefore appears that amyloid
inhibitory mechanism of D3 involves electrostatic-driven attraction to Aβ’s negatively
charged residues, which then prevents aggregation into toxic oligomers via a shielding of
Aβ’s aggregation nucleating sequence.
It then became crucial to determine the effect (if any) of D3 binding on the secondary
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Structure Aβ alone Aβ with D3 %∆
Coil 0.484 0.539 +11.36
Beta 0.162 0.125 -22.84
Bend 0.307 0.302 -1.63
Turn 0.037 0.025 -32.43
Table 5.2: The effect of D3 binding on Aβ42 monomer’s secondary structure. Given are the populations of each
secondary structure element in Aβ42 obtained from 100 10 ns MD simulations (averaged over time).
structure of Aβ42 monomer. In order to achieve this, the secondary structure content of
Aβ42 monomer in the bound and unbound states was calculated using the secondary struc-
ture prediction programme DSSP [73] interfaced to GROMACS. The secondary structure
results obtained as a function of time were then first averaged over time (i.e., 10 ns) and
subsequently over the 100 simulated systems. Table 5.2 presents the values obtained for
each secondary structural element. Comparing these values to those obtained form Aβ42
alone, it becomes obvious that the interaction of D3 peptide goes beyond a mere strong
binding to Aβ42 monomer. It also has a noticeable effect on the structure of the amyloid
peptide, which includes a significant reduction in β-sheet (−22.84%) and turn (−32.43%)
content accompanied by an increase in coil structure (−21.4%). D3 thus dissolves regular
Aβ42 structure into unstructured states, in agreement with staining experiment that re-
ported the absence of fibrillogenic property (i.e. β-sheet structure) in Aβ42 treated with
D3 [163,164]. This result partly explains the experimentally observed amyloid inhibitory
activity of the D-peptide involving the conversion of toxic fibrillogenic Aβ structure into
nontoxic nonfibrillogenic amorphous assemblies [162–164]. It thus further lends credence
to the belief linking Aβ structure and toxicity–that is, destroying toxic amyloid structures
provides a viable mechanism for Alzheimer’s disease therapy.
5.3.2 Aβ42 pentamer/D3
Using basin-hopping, 4000 Aβ42 pentamer-D3 complexes were generated and optimised,
and the binding energies ∆∆Gbind were calculated for the resulting complexes. The one
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hundred lowest ∆∆Gbind values (table 5.3) range from −222.22 kcal/mol to −160.42
kcal/mol with an average of -175.30 kcal/mol. This represents a gain in ∆∆Gbind of−41.44
kcal/mol compared with the average value of −133.87 kcal/mol for Aβ42 monomer-D3.
This does suggest a stronger affinity of D3 for higher-order Aβ oligomers (pentamer in
this case) than for the monomer.
The higher affinity of D3 to pentameric Aβ may partly be explained as resulting from
∆∆Gbind (kcal/mol)
-222.22 -183.54 -175.08 -169.42 -163.82
-205.93 -183.15 -174.78 -169.35 -163.78
-203.74 -182.69 -174.75 -169.34 -163.48
-203.37 -182.41 -174.55 -169.13 -163.23
-203.14 -181.89 -173.40 -168.79 -163.23
-201.75 -181.56 -173.33 -168.79 -163.09
-199.29 -181.47 -172.74 -168.63 -163.08
-198.42 -180.57 -172.71 -167.50 -163.08
-196.45 -179.84 -172.13 -166.58 -162.94
-194.43 -179.74 -172.00 -166.47 -162.76
-193.64 -179.15 -171.95 -166.26 -162.74
-192.98 -178.90 -171.65 -165.90 -162.70
-191.98 -178.13 -171.42 -165.36 -162.40
-188.70 -178.00 -171.27 -165.25 -162.39
-188.47 -177.41 -170.57 -165.22 -161.35
-188.26 -177.07 -170.51 -165.21 -161.27
-187.84 -176.56 -170.47 -164.94 -161.09
-184.51 -176.18 -170.30 -164.79 -160.86
-184.49 -175.96 -170.16 -163.90 -160.44
-184.46 -175.61 -169.96 -163.89 -160.42
Table 5.3: Binding energies (kcal/mol) of the one hundred Aβ pentamer-D3 complexes with the lowest ∆∆Gbind.
the bigger oligomeric size, which allows D3 to form more contacts with Aβ42 pentamer.
To provide a graphical representation of D3 binding, the D3 centre-of-mass was calculated
in each of the 100 systems:
rcom =
∑
i
miri
N
(5.7)
where mi and ri are atomic masses and coordinates, respectively. This transforms the
representation from atomic to molecular resolution, which becomes advantageous for rep-
resenting several interacting systems at the same time. In figure 5.6 D3’s centres-of-mass
in the one hundred systems are shown together with the Aβ42 pentamer to highlight
the interaction poses at a glance. The regular scaffold formed by the pentamer, unlike
monomeric Aβ42, enforces a more directed D3 binding. As would be expected, a large
proportion of the interaction is confined to the disordered but negatively charged sections
of the Aβ42 peptide, reminiscent of D3-Aβ42 monomer binding discussed above. A smaller
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proportion involves D3 interacting, at the same time, with the disordered and the β-sheet
ordered sections of the pentamer. Interestingly, in about 10 % of the observed complexes
D3 is able to bind within Aβ’s U-shaped β-sheet segment and interact directly with the
Asp23-Lys28 salt-bridge with the possibility to affect ordered fibril formation. The differ-
Figure 5.6: Overview of the interaction of D3 with Aβ42 pentamer. In yellow VDW radius the centres-of-mass
of D3 in the one hundred lowest ∆∆Gbind free energy configurations are shown superposed on Aβ42 pentamer
represented in green NewCartoon with acidic and basic residues shown in red and blue liquorice, respectively.
ent D3 binding regions must be independently considered as a variation in the binding
efficacy (i.e., the effect on structure) between different binding modes as against what was
obtained for Aβ monomer. Therefore, a cluster analysis was performed on the positions of
D3 around Aβ42 pentamer with the aim to identify regular patterns in the binding modes
(detail about the clustering in section 5.2.4). Fifteen clusters were obtained. After visual
inspection, six clusters were selected (figure 5.7) and subjected to 50 ns explicit solvent
MD simulation. Clusters 1, 4, 5, 6, 11 and 12 were selected based on the uniqueness of
binding poses, and involve D3 binding to both or either of the two termini residues of
the pentamer. Clusters 1, 5, 11, and 12 have the D3 residues at least partially piercing
through two adjacent chains of the pentamer in the N-terminal segment (cluster 1) or the
β-strand-forming segments (clusters 5, 11 and 12). And in clusters 4 and 6, D3 bridges
the length of the pentamer and interacts with both termini.
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As for the monomer, we analysed the effect of D3 binding on Aβ42 secondary structure
Figure 5.7: Six unique Aβ42 pentamer-D3 binding modes obtained after clustering. The yellow VDW represen-
tation shows D3, bound to Aβ42 pentamer represented in green NewCartoon with acidic and basic residues shown
in red and blue liquorice, respectively. (a) cluster 1, (b) cluster 4, (c) cluster 5, (d) cluster 6, (e) cluster 11, and
(f) cluster 12.
in the pentamer. The observed changes in Aβ42 helical structures for the six binding
modes are, for all purposes, insignificant. Although this is not surprising since helical
structures represent less than 3 % of the sampled structure. The situation, however, be-
comes drastically different in the case of β-sheet and random coil structures, with all six
binding poses being able to induce noticeable changes in the secondary structure of the
pentamer. All binding modes increased the coil content while reducing β-sheet structure,
but to greatly differing degrees. Cluster 6, where D3 binding exclusively to the disordered
region of Aβ, records the least changes in both coil and β contents. On the other hand,
binding poses with D3 simultaneously interacting with Aβ’s N-terminal and U-shaped
regions significantly reduce the β-sheet content. The strongest effect is observed for clus-
ter 12, in which D3 wedges between adjacent Aβ42 chains in the U-shaped section of the
pentamer. This leads to a disruption of the in-register backbone interaction (hydrogen
bonds and sidechain packing) as well as the Asp23-Lys28 salt-bridge, which can account
for the deletion of β-sheet. In clusters 1, 5 and 11 D3 concurrently interacts with Aβ’s
disordered end and the Glu22 residues oriented above the fibril plain, while in cluster 4
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the interaction involves the pentamer’s disordered region and Ile41 and Ala42 at the C-
termini. This diversity in D3 interaction with Aβ suggests the existence of many fruitful
binding modes in solution–fruitful because they all induce the desired reduction in Aβ’s
secondary structure. While it will be instructive to study the relative importance of the
different binding modes, such detail is unlikely to increase the understanding of the as-
sociation mechanism, especially, given the high degree of conformational plasticity and
heterogeneity associated with the oligomeric peptide Aβ. In other words, several of these
binding modes are likely to be concurrently significant, which will also partly explain the
transformation of β-sheet-rich Aβ into an amorphous mass rather than a single structure.
Figure 5.8: Secondary structure of Aβ42 in the pentamer with and without D3. The black histogram represents
the reference simulation, i.e., Aβ42 pentamer in the absence of D3.
5.3.3 Conclusions
Our study of the interaction between D3 and both monomeric and pentameric Aβ42
reveals important structural effects in both Aβ species that can explain the experimentally
observed inhibitory activities of D3, as well as structural aspects of amyloid toxicity
inhibition. The performed simulations reveal that D3 strongly binds to Aβ42 monomer and
pentamer, and in the process forms very stable complexes. Binding energy calculations
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reveal a stronger interaction with the pentamer. Binding of D3, in both Aβ species,
results in the disruption of regular secondary structure, β-sheet in particular, in favour of
random coil structure. This corroborates the experimental observation of Aβ structural
conversion into amorphous Tht-negative aggregates after treatment of a Tht-positive Aβ
solution with D3. Thus, the structural aspect of the inhibitory activity of D3 can be
explained based on the outcome of the present study. Our results reveal an electrostatic-
driven association between D3 and Aβ42 which possibly brings D3 to the self-recognition
unit of Aβ42. Our in silico study captures well salient structural aspects of an otherwise
complex in vitro situation, and even a more complex in vivo environment. In experiments,
the simultaneous presence of several thousand molecules of D3 and an heterogenous mix
of Aβ assemblies ranging from monomers to protofibrils and fibrils is likely to influence the
activity of D3. Under such conditions, D3 binding alone has the capability of significantly
altering Aβ size structure with each D3 molecule simultaneously binding different Aβ
units. The arginine-rich D3 may act as ”glue” onto which Aβ units stick. This alone
immediately destroys the intricate amyloid aggregation process that is crucially dependent
on a self-recognition-driven assembly, backbone hydrogen bond formation and sidechain
packing.
So far we have learned how D3 can bind to preformed β-sheets and start to disrupt them.
Future simulation will study he aggregation process of Aβ42 with and without D3 to learn
how D3 inhibits amyloid aggregation in the first place.
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Chapter 6
D3 Modifications
6.1 Introduction
An overarching aim of the lead identification stage of pharmaceutical drug discovery is the
identification of active compounds with the needed physicochemical profile such as molec-
ular size, lipophilicity, number of rotatable bonds, hydrogen bond-donating and -acceptor
groups. This allows the compound to possess the necessary pharmacokinetic attributes,
such as bioavailability, without which candidate compounds cannot progress through sub-
sequent stages of the discovery pipeline. In addition, lead optimisation is conducted (which
is more of an iterative process) in which the desired activity of the compound of interest
is improved upon (optimised) mainly via structural modifications relying on a knowledge
of the structure-activity relationship (SAR) of the compound. Most peptide drugs have
properties that frustrate their blood brain barrier (BBB) permeation, which constitutes
a major reason why peptide-based systems sometimes represent a poor choice in the di-
agnostic and treatment of neurological pathologies. For instance, D3’s molecular weight
of 1.6 kD and other molecular indices violating acceptable thresholds for druggability,
should either make it unfit for development, or then call for extensive chemical derivitisa-
tion to obtain agents with a better pharmacokinetic profile. For one, the preponderance
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of arginine residues in D3 (isoelectric point of 13.1) would normally make unassisted
BBB permeation difficult under physiological conditions. However, results from oral ad-
ministration of D3 to transgenic mice indicates that D3 is able to sufficiently permeate
the BBB and elicit its actions in the brain, suggesting the involvement of an assisted
transport mechanism [164]. In 2010, using a model consisting of rat’s brain microvascular
endothelial cells and astrocytes, Liu et al. demonstrated [180] that D3’s permeation of the
BBB involves a partly saturable BBB transport via the adsorptive-mediated transcytosis
mechanism [181] similar to that employed for ferrying strongly basic and arginine-rich
peptides across membrane barriers [181, 182]. The permeability, which was found to be
higher than that obtained for another second 12-residue D-peptide (codenamed D1, se-
quence QSHYRHISPAQV) with better lipophilicity than D3, showed a strong inhibition
by cationic agents such as polylysine, further lending supporting to the presence of a
facilitated BBB transport [180]. The result further highlights the importance of D3’s
five arginine residues in ensuring BBB permeation, as D1 with a single arginine residue
showed reduced permeability. The five arginine residues of D3 thus confer upon it the
ability to pass through the BBB to the brain where its actions are needed.
In the work reported in this chapter, we decided to determine if the desirable properties
of D3 can be improved upon. We performed in silico modifications of D3 involving minor
alterations of the D3 molecule. This way we did not risk losing the desirable features
of D3 and at the same time the ability to evaluate the properties of modified molecules
against those of D3.
6.2 D3 sequence reshuffling: RD2 and progenies
The first modification to the D3 structure involves a simple sequence reshuffling. The
fact that D3 demonstrates no pattern involving a huge relative importance for any of the
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non-arginine amino acid sequence suggests that the antiamyloid activity is expected to be
retained as long as the arginines are present. The sequence reshuffling involved pooling
together all the arginine residues at the C-terminus while the remaining residues are in
the N-terminus. This resulted in RD2, a D-peptide bearing 100% residue identity with
D3 peptide but having a different D-amino acid sequence:
PTLHTHNRRRRR
The construction of RD2 aims at designing a template molecule having the five arginine
residues as molecular arrowhead for targeted binding to Aβ, while small molecules possess-
ing β-sheet-breaking activities may be incorporated into the N-terminal via substitution.
In our simulation studies of RD2, the peptide was subjected to the same procedures (con-
formational search and interaction with both Aβ42 monomer and pentamer) as described
for D3 in the previous chapter. The starting structure, generated with CHARMM with
backbone φ and ψ angles set to 180◦ (figure 6.1(a)), was subjected to a 100 ns explicit
solvent MD run after which a cluster analysis revealed the structure in figure 6.1(b) as
the dominant conformation. In order to minimise repulsion, the sidechain groups of the
five successive arginine residues are arranged in whorl-like manner roughly spanning 360◦
around the backbone.
Two additional D-peptide models were obtained from the RD2 sequence, HN5 rep-
Figure 6.1: RD2 peptide model. (a) extended conformation before MD simulation. (b) dominant structure after
100 ns explicit solvent MD simulation with backbone coloured according to residue types with purple representing
arginine residues.
resenting the last seven residues with sequence HNRRRRR, and 5RS which is the
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penta-D-arginine group. Each peptide was subjected to explicit solvent MD simulation
as performed for RD2 and the dominant structures after cluster analysis of the resulting
trajectories determined (figure 6.2). All three D-peptides had an amidated carboxy ter-
minal. Adopting the study procedure described for D3, the interaction of each D-peptide
with Aβ42 monomer (employing five representative structures from the largest five clusters
obtained from Aβ42 conformational sampling in a 1.5 µs MD simulation) was investigated
using a combination of global optimisation, binding free energy calculations, and explicit
solvent MD simulations.
Figure 6.2: The two RD2 peptide progenies obtained after explicit solvent MD simulation: (a) HN5 and (b)
5RS. The backbone segment corresponding to arginine sequence is shown as purple tube.
6.2.1 Simulation protocol
With the aid of the oligomer-generation procedure [176] implemented into GMIN, 1000
Aβ42-D-peptide binary complexes were generated for each of the five Aβ42 starting struc-
tures, which were then subjected to 300 BH steps to optimise them employing dihedral
angle moves [177] and small rigid body rotations and translations [178] applied to the
D-peptides. Dihedral perturbation was performed with a 0.3 probability with a maximal
angle change of 30◦, while rigid body translation and rotation were performed with a 0.8
probability and a maximum displacement of 2 A˚ and 80◦, respectively. 5000 lowest energy
configurations were collected for each Aβ42–D-peptide system (1000 structures for each
of the five Aβ42 starting configurations) for which ∆∆Gbind was computed and employed
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for ranking the binding poses. Each of them was subjected to a 10 ns explicit solvent
MD simulation. The trajectories were analysed by averaging over time and the 100 sys-
tems, to obtain interaction energy maps between Aβ42 residues and D-peptide residues.
The simulations were then analysed to determine the effect of D-peptide binding on Aβ42
monomer’s secondary structure.
The interaction of RD2 with the full-length Aβ42 pentamer was subsequently studied as
for D3, i.e. 4000 Aβ42 pentamer-RD2 complexes were generated and optimised in 400
basin-hopping steps. Here, a maximum angle of 90◦ was allowed for rigid body rotation
with 1.0 probability and a maximum translation of 2 A˚ was applied to RD2 at every BH
step. The lowest energy Aβ42–RD2 complexes were collected and ranked using calculated
∆∆Gbind (as described in section 2.2.1). The distribution of RD2 around Aβ42 pentamer
was then determined by calculating the centre-of-mass of RD2 in each of the 100 binding
poses having the most favourable ∆∆Gbind values. Based on the RD2 position in the
complexes, a cluster analysis was performed with a 2.9 A˚ RMSD cutoff yielding 15 clus-
ters. Representative structures for six clusters with sufficiently different binding patterns
were selected and each subjected to a 50 ns explicit solvent MD simulation using the same
simulation parameters as for D3-Aβ42 pentamer. The outcome were then compared to
the 50 ns reference simulation of unbound Aβ42 pentamer.
6.2.2 Results and discussion
The top 100 Aβ42 monomer-RD2 binding poses have ∆∆Gbind values ranging from −177.4
to −114.3 kcal/mol, representing an improvement in binding for the complex of −7
kcal/mol compared with D3 (lowest ∆∆Gbind of -170.8 kcal). The situation between
the two D-peptides however reverses when considering the average binding energy values
(∆∆G¯bind), −128.0 kcal/mol and −133.9 kcal/mol for RD2 and D3, respectively. This
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seems to indicate that both RD2 and D3 generally display a similar pattern of binding
to monomeric Aβ42. However, this is not surprising given that RD2 and D3 share 100
% residue similarity, the only difference being the sequence, which is not expected to
significantly affect the electrostatic-driven association between the D-peptides and Aβ42
monomer.
However, moving on to the shorter seven-residue HN5 and the five-residue 5RS peptides,
a second factor influencing interaction with Aβ42 monomer seems to emerge. Despite the
fact that HN5 and 5RS also contain five arginine residues as RD2 and D3, they exhibit
much higher ∆∆G¯bind values than the 12-residue D-peptides (table 6.1). Additionally,
HN5 is better bound to Aβ42 monomer than 5RS, which suggests the larger interaction
surface in the longer D-peptides as well as additional contributions from non-arginine
residues are important for binding of the D-peptides to Aβ42. Normalising ∆∆G¯bind to
the number of residues,
∆∆G¯res =
∆∆G¯bind
Nres
(6.1)
where Nres is the number of residues in the D-peptide. We find that ∆∆G¯res values for
HN5 (−14.8 kcal/mol) and 5RS (−18.6 kcal/mol) are more favourable than the values
for RD2 (−10.7 kcal/mol) and D3 (−11.2 kcal/mol). However, this appears to result
from the increasing relative number of D-arginine residues going from the 12-residue
RD2 and D3 (41.7 %) to the penta-D-arginine 5RS (100 %). This further reveals the
relative importance of arginine residues in driving the interaction. ∆∆G¯res for 5RS is
markedly different from the other three systems, principally because the other systems
contain non-arginine residues unlike 5RS. In order to properly describe the contributions
of the different residues, especially in D-peptides containing non-Arginine residues, it is
necessary to calculate ∆∆G¯Arg and ∆∆G¯X,X 6=Arg, respectively representing the averaged
contributions of arginine and non-arginine residues to ∆∆G¯int (table 6.1).
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Aβ System % Arg ∆∆G¯bind ∆∆G¯res ∆∆G¯
?
Arg ∆∆G¯
?
X,X 6=Arg
Aβ42 monomer
D3 41.7 -133.9 -11.2 -16.5 -11.1
RD2 41.7 -128.0 -10.7 -18.8 -9.6
HN5 71.4 -103.9 -14.8 -16.8 -11.6
5RS 100.0 -93.1 -18.6 -18.1 -
Aβ42 pentamer
D3 41.7 -175.3 -14.6 - -
RD2 41.7 -182.2 -15.2 - -
Table 6.1: Binding free energies for D-peptide Aβ42 complexes in kcal/mol. The ∆∆G¯? values were obtained
using GROMACS and ffG53a6.
Following the explicit solvent MD simulations of the selected 100 binding poses for RD2-
Aβ42 monomer, HN5-Aβ42 monomer and 5RS-Aβ42 monomer, a decomposition of the
time-averaged interaction energy into inter-residue contributions was performed and av-
eraged over the 100 complexes. This generated the interaction energy maps presented
in figure 6.3 (the map for D3 has been included for comparison). While a pattern of
electrostatic-driven binding similar to that for D3-Aβ42 monomer is also obtained for
RD2, HN5, and 5RS, the three D-peptides display a generally higher preference for the
acidic residues of Aβ42. The number of residue-residue contacts with interaction energies
lower than −2.00 kcal/mol is much higher for RD2 than for D3. As the relative D-arginine
content increases from RD2 through 5RS so does the number of interactions with energies
close to −3.00 kcal/mol. It is however interesting to note the increased preference for
Aβ42’s N-terminal residues 1→11 with increasing relative D-arginine content. 5RS almost
exclusively binds Aβ42 monomer at residues 1→11; completely avoiding Glu22 while the
strength of interaction with Asp23 has also reduced to ≈ −1.40 kcal/mol. This is partly
a result of electrostatic repulsion between the penta-D-arginine and Lys28 of Aβ as the
interaction map for 5RS shows. As the number of non-arginine residues increase in the
RD2 family, so does the interaction strength with Glu22-Asp23 of Aβ (≈ −2.20 kcal/mol
and −3.00 kcal/mol respectively in HN5 and RD2). RD2 containing seven non-arginine
residues also interacts mildly with the hydrophobic C-terminal half of Aβ. Compared
to D3, RD2 more selectively binds Glu11 and Asp23 of Aβ42 monomer. ∆∆G¯Arg and
∆∆G¯X,X 6=Arg values for D3 and RD2 in table 6.1 suggest a probable cause for this. With
the five D-arginine residues pooled in the C-terminal half of the peptide, RD2 demon-
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strates a more favourable ∆∆G¯Arg of −18.79 kcal/mol compared with −16.49 kcal/mol
for D3. This partly explains while RD2 demonstrates higher selectivity for Aβ’s Glu11
and Asp23. There is however a trade-off with respect to a less binding favourability
of the non-arginine residues in RD2 (∆∆G¯X,X 6=Arg −9.60 kcal/mol) compared with D3
(∆∆G¯X,X 6=Arg −11.06 kcal/mol). This can also be seen in figure 6.3(c) where D3 is seen
to form more extensive interactions with non-charged residues of Aβ than RD2.
∆∆G¯bind value obtained for the binding of RD2 to Aβ42 pentamer differs by −6.9
Figure 6.3: Interaction energy maps for Aβ42 monomer residues and (a) RD2 residues, (b) HN5 residues, (c)
D3 residues, and (d) 5RS residues.
kcal/mol from that of D3 (table 6.1). RD2 thus exhibits slightly stronger binding than
D3 to Aβ42 pentamer. In addition, the lowest ∆∆Gbind value of −272.52 kcal/mol ob-
tained for RD2 is substantially lower than the corresponding value of −222.22 kcal/mol for
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D3. The presence of a better structurally defined binding partner in Aβ42 pentamer, com-
pared with the largely unfolded Aβ42 monomer, might hold a special significance for this
relatively large disparity in the binding of RD2 and D3. The ordered stacks of five Asp23
residues within the fibril core of Aβ42 pentamer and the five Glu22 residues immediately
above it (figure 6.4) possibly provide a better binding surface for the penta-D-arginine
groups of RD2 which are absent in D3. This is captured in figure 6.5 which presents the
distribution of RD2 and D3’s centers-of-mass around Aβ42 pentamer.
RD2 binding modes are divided into two classes in which interaction is either restricted
Figure 6.4: A view of the frontal section of Aβ42 pentamer showing Phe20 → Gly33 in green cartoon. The
five Asp23 residues inside the fibril core and the Glu22 above appear in red liquorice, and Lys28 residues in blue
liquorice.
to Aβ42 pentamer’s disordered segment, or to the hydrophobic U-shaped fibril core bear-
ing Asp23 and Glu22 residues. This sharply contrasts with D3 which is distributed more
widely around the Aβ42 pentamer. Of the top 100 binding poses, RD2 centres-of-mass
within the fibril core can be found 41 times, compared with 16 for D3. In other words,
RD2 is ≈ 2.6 times better at targeting Aβ42 pentamer’s fibril core compared to D3. This
thus suggests that the reshuffling of D3 residues into RD2 with the five D-arginine con-
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centrated at the C-terminus significantly enhances its ability for focussed binding to the
fibril core of the Aβ42 pentamer.
This brings us to the important question: how does the observed binding pattern trans-
Figure 6.5: Binding of (a) RD2 and (b) D3 to Aβ42 pentamer. The centre-of-mass of RD2 and D3 in each
of the selected 100 binding poses is shown as yellow balls, residues 1–20 of Aβ42 pentamer are represented with
transparent ribbon, while residues Phe20–Gly33 have been shown in green NewCartoon. The fibril core’s five
Asp23, Glu22 (red) and Lys28 residues (blue) are represented in liquorice. The backbone groups of the acidic
(red) and basic (blue) residues within Aβ42’s disordered segment are also shown as liquorice.
late into structural efficacy in monomeric and pentameric Aβ42 peptides? To this end,
the trajectories for the 100 Aβ42 monomer-D-peptide systems were analysed for secondary
structure composition and the average over the 100 systems calculated. This was repeated
for the unbound Aβ42 from each of the predictions to provide a suitable control analysis.
The changes in secondary structure between the bound and unbound Aβ42 structures were
then calculated and expressed as percentage change as shown in table 6.2. The percentage
changes were calculated in such a way that a negative value represents a decrease in the
respective secondary structure element while a positive value represensts an increase. Out
of the four D-peptides, D3 and RD2 binding induce the largest changes in Aβ42 monomer
structure consisting mostly in β structure destruction and increased coil content. How-
ever, the effect of D3 is conspicously higher than that of RD2, which is likely to be a result
of the higher level of D3 interaction with the hydrophobic residues of Aβ42 monomer (fig-
ure 6.3). Figure 6.3 shows D3 as relatively more readily interacting with the two stretches
of hydrophobic residues (17–21 and 30–42) with interaction energies in the order of −0.72
kcal/mol compared with > −0.24 kcal/mol for the RD2 family. Both HN5 and 5RS only
114
D3 Modifications 6.2 D3 sequence reshuffling: RD2 and progenies
mildly affect the Aβ structure. In conclusion, the RD2 family of D-peptides’ increased
targeting of Aβ42 monomer’s acidic residues fails to translate into better structural effect
in Aβ42 monomer.
RD2 binding positions on Aβ42 pentamer were subjected to geometric clustering that
D-peptide Beta (%∆) Coil(%∆) Bend(%∆) Turn(%∆)
D3 -22.84 11.36 -1.63 -32.43
RD2 -15.09 5.53 1.95 -20.00
HN5 -3.66 0.60 1.68 -8.33
5RS -4.07 1.00 2.03 -15.38
Table 6.2: Percentage change in Aβ42 monomer’s secondary structure following D-peptide binding
generated 15 clusters (in line with the number obtained for D3). Six of these clusters
(figure 6.6) were each subjected to 50 ns MD simulation in explicit solvent. The trajec-
tories were analysed and the sampled secondary structure contents were determined and
compared to the reference (control MD simulation of unbound Aβ42 pentamer). As can
be observed in figure 6.6 RD2 binding, especially in clusters 2, 7 and 13, appears to induce
much larger disruption of the Aβ42 pentamer structure than did D3. Figure 6.7 shows
secondary structure analysis and how the selected representative cluster centres compare
with the D3-Aβ42 pentamer complexes.
On a general note, RD2 more strongly inhibits β structure while at the same time
increases coil content compared with D3. When RD2 binds along the fibril axis (i.e.
perpendicular to the β-sheet) as in clusters 8 and 9, the effect on the Aβ42 secondary
structure is maximised. This represents a deviation from the pattern obtained for Aβ42
monomer in which D3, as a result of the ability to form more widespread interaction with
Aβ generated higher structure-disrupting influence on the amyloid peptide. Experimental
measurements on different D-peptides including D3 and RD2 reported RD2 as possessing
higher amyloid-inhibiting effect than D3 peptide (Oleksandr Brener, personal commu-
nication). However, the relative amyloid-inhibitory effect of the two D-peptides under
experimental conditions will very likely also depend on the relative abundance of different
Aβ species, with D3 likely to have a higher effect on monomeric and less structured Aβ
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Figure 6.6: Six unique Aβ42 pentamer-RD2 binding modes obtained from cluster analysis. The yellow VDW
representation shows RD2 (the penta-D-arginine can be distinguished by its non-transparent representation),
bound to Aβ42 pentamer, which is shown in green NewCartoon with acidic and basic residues shown in red and
blue liquorice, respectively. (a) cluster 1, (b) cluster 2, (c) cluster 7, (d) cluster 8, (e) cluster 9, and (f) cluster
13.
Figure 6.7: Effect of D-peptide binding one Aβ42 pentamer secondary structure. On the left is the plot of
changes resulting from RD2 binding, and on the right is a plot of changes from D3 binding. Generally, RD2
demonstrates much stronger effect Aβ42 pentamer structure than D3.
species, while RD2 preferentially inhibits more structured Aβ oligomers.
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6.3 D3 mutations with natural and non-natural amino
acids
6.3.1 Mutation studies with Aβ42 monomer
The second category of modifications performed involve replacement of each amino acid
sequence of D3 with the remaining nineteen possibilities. These mutations were performed
for each of the 100 Aβ42 monomer-D3 complexes with the lowest ∆∆Gbind values. That
is, with each of the 100 complexes as starting structure, each of the D-amino acid residues
of D3 was replaced with the other 19 D-amino acid residues to produce new complexes
bearing the modified D-peptides. Glycine and proline residues were not substituted into
the first sequence position; accounting for these two exceptions, the total number of amino
acid substitutions is:
Nmut = (17 + 11× 19)× 100 = 22, 600 (6.2)
We used the MMTSB tool set [183] to carry out the mutations using parameters from
the CHARMM22 force field for topology definition [170]. Each of the resulting mutant
system was first subjected to energy minimisation to eliminate atomic clashes resulting
from the substitutions. Using the binding free energy calculation method described in
the previous chapter for D3, ∆∆Gmutbind was subsequently calculated for each of the 22,600
mutants. The deviation of ∆∆Gmutbind from ∆∆G
orig
bind was then calculated:
∆∆Gdiffbind = ∆∆G
mut
bind −∆∆Gorigbind (6.3)
where ∆∆Gorigbind is the energy for the corresponding precursor D3-Aβ42 monomer complex.
From equation (6.3) it follows that any mutation improving the binding for a particular
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amino acid position will have a negative ∆∆Gdiffbind , and vice versa. Lastly, the average
for each mutation was calculated over the 100 different binding poses and the standard
deviations determined.
Out of 226 point mutations presented in figure 6.8, only ten show slight improvement
Figure 6.8: D3 substitution with natural amino acids for binding to Aβ42 monomer. D3 residues appear on
the vertical axis while the replacement D-amino acids are on the horizontal axis. The white circles represent non
applicable substitutions involving self-substitutions (e.g., Arg replacing itself) and the omitted Pro and Gly at
the N-terminus.
(i.e., ∆∆Gdiffbind < 0) over the original D3. This suggests that D3 represents a highly opti-
mised sequence in particular with respect to its Aβ monomer binding activity. Four of the
substitutions have ∆∆Gdiffbind values only slightly lower than zero and these are Thr8→Leu,
Arg1→Asn, His7→Lys and Thr8→Ala. Replacing Arg1 with Ser brought about the high-
est observed improvement with a ∆∆Gdiffbind value of of −10.5 ± 1.18 kcal/mol, followed
by His9→Met and Arg3→Ala with −7.60 ± 1.09 kcal/mol and −5.31 ± 1.15 kcal/mol
respectively. Changing Arg1→Leu and Thr4→Ser resulted in −4.50± 1.21 kcal/mol and
−4.08 ± 0.92 kcal/mol, respectively. The binding enhancing mutations may be put to-
gether to produce the sequence (A),
(A): SPASRLKLMRAR
(B): RPRTRLHTHRNR
where Pro2, Arg5, Leu6, Arg10 and Argr12 of D3 are all conserved. The sequence (B) is
the D3 peptide. The introduced ’KLM’ group vaguely resembles Aβ42’s self-recognition
unit that is critical for fibril assembly. Interestingly, the proposed sequence changes sup-
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port a more hydrophobic N-terminal segment for the D-peptide which mildly echoes the
sequence pattern in RD2. In this regard, the mutant peptide is likely to improve D3’s
affinity for Glu22-Asp23. This, however, may not directly translate into structural efficacy
considering that D3 demonstrated better destruction of the β content in Aβ42 monomer
than RD2. However, considering the fact that the mutations increase the peptide’s net
hydrophobicity from 5 charged and 2 hydrophobic residues in D3 to 4 charged and 5 hy-
drophobic residues in the mutant, increased hydrophobic interactions (∆∆G¯X,X 6=Arg/Lys)
in the new sequence with Aβ42 monomer will likely improve binding efficacy.
Another interesting observation is that the three aromatic amino acids, Phe, Tyr, and
Trp as well as the acidic amino acids, Asp and Glu, are strictly forbidden, i.e., they in-
creased ∆∆Gbind. Substitution with Asp or Glu is likely to interfere with the crucial role
of D3’s arginine residues via repulsive interaction with the acidic residues of Aβ42. The
avoidance of the aromatic residues points to a likely influence of chemical structure, in par-
ticular steric hindrance disallowing the replacement of D3’s residues with large aromatic
side-chains. In addition, the Thr→Ser mutation suggests that the 4th D-peptide position
is better occupied by a hydroxymethyl group of serine than threonine’s 1-hydroxylethyl
group. On the other hand, methionine’s -CH2SCH3 side-chain is preferred to histidine’s
imidazole ring at position 9.
6.3.2 Mutation studies with Aβ42 pentamer
The same kind of mutation study was repeated for Aβ42 pentamer, but with three im-
portant modifications:1) Some selected non-natural amino acids were included; 2) the
mutations were performed on both D3 and RD2 sequences and ; 3) the programme for per-
forming the point mutations was changed to Modeller [184] (used with the CHARMM22
force field [170]) that allows the definition of non-standard molecules. This represents an
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initial attempt at diversifying the molecular structure of the two D-peptides and incorpo-
rating wider chemical classes. Starting with the top 100 D3-Aβ42 pentamer and RD2-Aβ42
pentamer structures used for the above described interaction study, each residue of D3
and RD2 was mutated to one of the other 19 natural and the seven non-natural amino
acids. The structures of the non-natural residues, after geometry optimisation at the
semi-empirical level of theory (PM6)[185], are shown in figure 6.9.
Binding free energy calculations, as described under section 6.3 were performed and
Figure 6.9: Structures of the non-natural amino acids employed for mutation. Structure generation and geometry
optimisation were performed with Spartan’10 [12].
∆∆Gdiffbind of resulting mutant D3 calculated for the Aβ-D3 bound systems (total of
12 × 24 × 100 = 28, 800 mutations). In the case of RD2, the penta-D-arginine group
shown to be crucial in RD2’s interaction with Aβ42 was kept, so that the substitutions
were restricted to the seven non-arginine residues producing a total of 7×24×100 = 16, 800
mutations.
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6.3.3 Results and discussion
The obtained ∆∆Gdiffbind values the D-peptide–Aβ42 pentamer differ from the values ob-
tained for the Aβ monomer mainly as a result of the differences in the extent of the
D-peptide’s interaction with the Aβ peptides. Interaction with Aβ42 monomer involves
less extensive peptide contacts than with Aβ42 pentamer; this, perhaps, partially accounts
for the fewer number of free-energy-improving substitutions obtained in the former. The
higher extent of contact in the D-peptide–Aβ pentamer, however, comes with certain im-
plementation challenges in which some of the systems returned very high ∆∆Gbind values
resulting from serious clashes involving residues with large sidechain groups. Examples
include BPP with a benzoylphenyl sidechain, and NPA with a naphthalyl sidechain, which
as seen in figures 6.10 and 6.11, are too large to be accommodated within the D-peptide-
Aβ42 pentamer tightly bound complexes. Nevertheless, their energies were not excluded
since they provide useful information about unfavourable energetics of the concerned
residues.
In other words, BPP and NPA are disfavoured in both D3 and RD2 peptides mostly
Figure 6.10: D3 optimisation by amino acids substitutions for binding to Aβ42 pentamer. D3 residues are listed
on the vertical axis while the substituting D-amino acids are on the horizontal axis. The white circles represent
zero ∆∆Gdiffbind for self-substitution, e.g., replacing Arg residue with itself.
because of unfavourable size. In the case of D3, however, the picture changes signifi-
cantly going from BPP and NPA, with two-ring aromatic sidechains, to one-ring aromatic
sidechain where changing Pro2→Phe, Leu6→Trp, Leu6→Phe, Leu6→Tyr, Leu6→FPA,
and Asn11→Tyr result in some of the most favoured substitutions. While the replace-
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ment of Pro2 and Leu6 with hydrophobic and aromactic residues represents a significant
majority of the favourable substitutions, D3’s arginine residues are all strictly conserved.
This tends to suggest that the arginine residues play a more crucial role in binding Aβ42
pentamer than they do in Aβ42 monomer. Also, the fact that aromatic substitutions are
disallowed in D3-Aβ42 monomer complexes while they are allowed in D3-Aβ42 pentamer
complexes suggests that aromatic substitutions may be important for designing D-peptide
inhibitors with increased specificity for Aβ42 oligomers.
The pattern observed in RD2 substitutions is similar to that of D3, especially in the
Figure 6.11: RD2 optimisation by amino acids substitutions for binding to Aβ42 pentamer. D3 residues are
listed on the vertical axis while the substituting D-amino acids are on the horizontal axis. The white circles
represent zero ∆∆Gdiffbind for self-substitution, e.g., replacing Arg residue with itself.
preference for hydrophobic and aromatic substitutions. However, many more favourable
amino acid substitutions are possible in RD2 than in D3 peptide. For example, RD2’s pro-
line in position 1 accommodates most of the substitutions with the exception of Trp, GAB,
HCT, LBH, and NPA. The higher chances of substitution observed for RD2 compared
with D3 may have resulted from the specific nature of RD2’s binding to Aβ42 pentamer.
By mostly utilising its penta-D-lysine group for interacting with Aβ42 pentamer, RD2
makes its seven non-arginine residues relatively more available for substitution than D3
where the staggering of the five D-arginine residues along the entire sequence makes it
difficult to introduce substitutions that do not affect interaction. From the non-natural
residues, only FPA replacement of Leu6 produces favourable ∆∆Gdiffbind for D3-Aβ42 pen-
tamer, while for RD2 FPA replacement of Pro1, Leu3, His4, as well as PGL replacement
of Pro1 and Leu3 improve Aβ42 pentamer binding. That is, RD2 provides a better molec-
ular template for chemical modifications than D3.
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A closer look at the substitutions involving single-ring aryl sidechains such as Phe, Tyr,
FPA (4-fluorophenylalanine), and PGL (phenylglycine) in figure 6.11, seems to suggest
a distinct pattern. Replacing Thr5 and Asn7 with Tyr is unfavourable, suggesting a
disallowing of the aromatic OH group at this position. Interestingly however, replacing
Tyr’s hydroxyl group with a flouride (FPA) at this position produces a favourable bind-
ing energy. Phe, Tyr, and FPA produce an identical effect when replacing Leu3 and
Thr5 (∆∆Gdiffbind ≈ −10 kcal/mol) and Pro1 (∆∆Gdiffbind ≈ −12 kcal/mol), suggesting the
effect here mostly results from the phenyl ring. However, with the sidechain shortened
by a methylene group, as seen in PGL, the number of favourable substitutions reduced
from 3, in Phe, Tyr and FPA, to 2 in PGL where substitution is only allowed for Leu3
(∆∆Gdiffbind ≈ −12 kcal/mol) and Pro1 (∆∆Gdiffbind ≈ −10 kcal/mol). Only Leu3→PGL
can be considered seriously given the fact that Pro1 is generally open to all substitutions
including BPP. Apart from PGL, valine and histidine also successfully replace Leu3 which
seems to suggest this position in RD2 prefers sidechain groups that are slightly smaller
than a benzyl group. Lastly, the incorporation of FPA provides a means of improving the
lipophilicity of the molecule, should that be desired, since flourine in the para position
has the ability of improving both the lipophilicity and stability of the aromatic ring [186].
6.3.4 Conclusion
Using sequence shuffling and about 700 hundred different point mutations, we examined
the effect of amino acid sequence modifications on the binding free energies of D3 inter-
acting with Aβ42 monomer and pentamer. Pooling the five D-arginine residues present
in D3 to the C-terminus produces RD2, a reshuffled form of D3 with a penta-D-arginine
sequence expected to facilitate targeted binding of the D-peptide to Aβ42’s acidic residues.
We performed an assessment of the binding free energy as well as the effect of binding
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on Aβ42 monomer and pentamer structures. A comparison of RD2 with D3 resulted in
an identical pattern of binding to Aβ42 monomer dominated by electrostatic attraction
between the D-arginine residues of D3 and RD2 and Aβ’s acidic amino acid residues.
However, while D3 prefers to interact with Aβ42’s Glu22 and Asp23, RD2 demonstrates
a slightly higher preference for Glu11 and Asp23. A deconvolution of the binding energy
shows that the five D-arginine residues are more efficiently employed in RD2 than in D3.
However, while interacting with Aβ42, D3 additionally utilises several energetically weak
hydrophobic contacts. While both D-peptides demonstrate β-sheet breaking effect on
Aβ42 monomer, the fact that D3 more significantly affects Aβ’s structure demonstrates
the importance of hydrophobic contacts to overall binding.
Sequential removal of RD2’s non-arginine residues almost completely abolishes the β-sheet
breaking effect, further supporting the contribution of hydrophobic interactions. Visual
examination of D3-Aβ42 monomer complexes and interaction energies suggests the em-
ployment of binding poses which allows D3 to interact with Aβ42’s hydrophobic sequences
that are often involved in β-sheet formation. This explains the higher structural effect
obtained for D3 compared with RD2 in the Aβ42 monomer complexes.
The pattern, however, reverses in Aβ42 pentamer systems. Interestingly, the penta-D-
arginine group of RD2 renders it better able to interact with Asp23 existing deep within
Aβ42 pentamer’s hydrophobic core. In this regards, compared with D3, we have shown
that RD2 is approximately thrice as likely to penetrate into Aβ42 pentamer’s fibril core.
Drawing inference from the energetic pattern seen in Aβ42 monomer, RD2’s binding may
be a consequence of the increased binding effectiveness observed for the D-arginine residues
in RD2. In addition, it explains the higher destruction of Aβ42 pentamer’s β-sheet ob-
tained for RD2 than for D3. We further observed that the structural effect of D-peptide
binding in both RD2 and D3 correlates well with the binding site within Aβ42 pentamer.
The two peptides produce the largest effect on Aβ structure when bound to the β-sheet-
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forming regions than when bound to the disordered N-termini. However, it may be
possible that the in vitro and in vivo anti-amyloid effects reported for the two D-peptides
are mediated via both binding modes.
Results from the amino acid substitutions reveal D3 as already highly optimal for binding
Aβ42 monomer. Replacing Arg1 and His9 with Ser and Met, respectively, produced the
highest improvement in binding free energy. We also observed that substitution of D3’s
Pro1, Arg5, Leu6, Arg10 and Arg12 is strongly disallowed, and that aromatic residues are
generally not favoured over existing D3 residues. This pattern, however, changes slightly
with D3-Aβ42 pentamer and RD2-Aβ42 pentamer systems where more substitutions are
allowed than for the Aβ42 monomer. This further supports the position that D3 sequence
is highly optimised for monomeric Aβ. Using substitutions with natural and seven non-
natural amino acids, we observe that certain amino acid positions in the D3 sequence
demonstrate selectivity for a particular chemical class. The fact that single-ring aromatic
substitutions are favoured over other groups suggests the possibility of using these groups
in designing inhibitors with improved selectivity for Aβ42 oligomers.
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6.4 Supplementary information: Force field parame-
terisation
In the quantum chemical description of molecular systems, molecules are modelled as
collections of interacting electrons and nuclei. Various levels of approximations are used
in order to solve the molecular Schro¨dinger equation, which expresses the total energy of
an electronic system as an eigen-equation:
HˆΨ = EΨ (6.4)
Here, Ψ is a wavefunction representing the electronic state, and when operated upon by
the Hamilton operator, Hˆ, the system energy is obtained. For the simplest case, which
is the hydrogen atom–the only system for which the equation has an exact solution–the
equation expands (in atomic units) into,
(
−1
2
∇2 − Z
r
)
Ψ(r) = EΨ(r) (6.5)
which captures both the electronic kinetic (first term in the equation) and potential energy
(second term in the equation). The distance r is the separation between the electron and
the nucleus having a nuclear charge Z (Z = 1 for H) and r is the 3D coordinate of the
electron. The Schro¨dinger equation for polyelectronic systems includes terms for electron-
electron, electron-nucleus, and nucleus-nucleus interactions:
HˆΨ(r,R) = EΨ(r,R) (6.6)
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where the Hamiltonian operator is given by:
Hˆ = −1
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(6.7)
where rij is the distance between electrons i and j, RAB is the distance between nuclei A
and B, and riA is the separation between electron i and nucleus A. This equation can-
not be solved analytically. Approximations introduced to make it numerically tractable
include the Born-Oppenheimer approximation that neglects the nuclear motion removing
the third term in equation 6.7 and turning the 4th term into a constant. The Hartree-Fock
(HF) model derives from the similarly named approximation in which the wave function
of the system can be approximated by a single Slater determinant, which considers Ψ for
a collection of electrons, each with a wave function known as spin orbital. By invoking the
variational method, one can derive a set of Nspin-coupled equations for the Nspin spins.
The Hartree-Fock system gave birth to semi-empirical models which neglect non-valence
electrons and use much fewer basis sets than the HF models. Finally but importantly,
semi-empirical models also employ approximations that allow the incorporation of empiri-
cal terms, which coupled with its computational efficiency and the availability of basis sets
for calculations relating to transition metals make semi-empirical method a good choice
for systems containing up to few hundreds of atoms. In this work, the semi-empirical
method PM6 [185] as implemented in the quantum chemistry package Spartan’10 [12]
was employed to derive force field parameters for 7 non-natural amino acids.
Following energy minimisation, the equilibrium geometries for the seven non-natural
amino acids were used to determine the molecular mechanics parameters compliant with
the
CHARMM27 potentials. With the newly generated CHARMM parameters a 10 ns MD
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simulation in explicit solvent using the MD programme NAMD [187] was performed for
each molecule to confirm that the parameters did not sample unreasonable conformations.
The parameters were thereafter employed for conducting the amino acid substitution in
the bound D3-Aβ42 pentamer and RD2-Aβ42 pentamer systems.
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Summary and Future perspectives
The past decades have witnessed a great deal of research activities into the role of Aβ
peptide in the development of Alzheimer’s disease. While increasing number of biochem-
ical pathways have been discovered to be involved in AD development, research findings
have also increasingly supported the involvement of the Aβ peptide in many of these
pathways. For instance, there is a good documentation of the neuronal toxicities of differ-
ent Aβ alloforms and oligomeric sizes, which understanding has also motivated targeting
of Aβ associated pathways in Alzheimer’s drug design. However, the very fact that no
definitive treatment currently exists for Alzheimer’s disease highlights the associated level
of complexity. Unlike other drug targets, the small oligomers of the Aβ peptide, which are
rightly believed to be the main toxic species, lack a unique three-dimensional structure.
In addition, their significantly high aggregation rates make it difficult to employ powerful
tools like solution NMR, for Aβ structure determination. This has prompted the employ-
ment of artificial solubilising conditions such as the use of organic solvents in structure
determination. The problem with this approach is that the obtained structures, which
are often helical, do not exactly represent the physiological state under which conditions
Aβ is believed to mostly sample β-sheet and random coil structures.
Using the ability of molecular simulations to focus attention on a single molecule, we
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studied the conformation dynamics of Aβ peptides. To limit force field bias, we employed
long MD trajectories and validation with NMR chemical shifts to select the force field
that best models Aβ40 and Aβ42 monomers’ physiologic conformations. Only the force
field ffG53a6 sufficiently reproduced the NMR chemical shifts for both Aβ40 and Aβ42
monomer, and captured the fast conformational transitions associated with an intrin-
sically disordered peptide (IDP) like Aβ. The force field shows both peptide as being
essentially unstructured in the N-terminal segment, but with Aβ40 slightly more disor-
dered than Aβ42. In addition, it shows the self-recognition unit sequence
16KLVFF20 as
forming β-sheet in both peptides but to a slightly higher extent in Aβ42, in which a Gly37-
Gly38 turn thought to distinguish Aβ42 from Aβ42 was also correctly sampled. Cluster
as well as secondary structure analyses revealed Aβ42 as more rigid and a better β-sheet
former than Aβ40. Importantly, our results agree well with experimental findings, sug-
gesting that the behaviour of the two peptides in a laboratory set up involving thousands
of molecules, can be explained at a single molecule level using molecular simulation. This
is also true with respect to the conformations sampled by Aβ42 under the different pH
conditions we modelled based on amino acid charged states. Previous experiments had
indicated that the structure and aggregation of Aβ are largely affected by pH. In our
in silico experiment, we observed the Aβ42 conformation to depend on the protein net
charge. The observed structural effect is most dramatic at the isoelectric pH 5.4 where
the highest percentage of β-sheet is formed resulting from a minimisation of electrostatic
repulsion. His6 was observed to play a critical role in ordering intramolecular contacts and
facilitating secondary structure formation. We believe this explains, at a single molecule
level, the high aggregation propensity associated with the peptide at slightly acidic pH.
The weakness of our approach is however also associated with the ability to single out
individual molecules for investigation. Atomistic simulations are still unable to handle
system sizes comparable to what can be achieved in experiments. In addition, there is
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the risk of mismatching protein system and force field capabilities mainly because there
is still no universal protein force field. Instead the design of the currently available force
fields restricts their very use to systems not too much different from those for which they
were designed. For instance, the factors driving the conformational properties of IDPs
are sufficiently different from most globular proteins, which probably explains why most
existing force fields have not been as successful with IDPs as they have been with natively
folded proteins. Most of the existing protein force fields have been observed to correctly
predict protein folding rates as well as native state conformations, while the performance
with respect to the features of the unfolded state and the folding mechanism depends
heavily on the choice of force field. It therefore becomes evident, that the inability of
the force field ffG43a2 to sample the correct structural ensemble for Aβ emanates from a
restriction of its applicability to folded protein systems for which it has been largely suc-
cessful. On the other hand, the success of the ffG53a6 force field for modelling Aβ is likely
because it was parametrised to reproduce both the free enthalpies of hydration and apolar
solvation which are important factors in most biomolecular processes. In other words, Aβ
conformational states obtained for ffG53a6 result from the choice of the parameter set
and not vice versa. Our results further highlights the need for a proper benchmarking of
the protein force fields, and in particular for the need to broaden the selection of protein
test sets beyond natively folded proteins to include IDPs. In addition, the benchmarking
may include validation with experimental observables such as chemical shifts.
Using a combination of global optimisation, binding free energy calculation and MD
simulation methods, we investigated the interaction of amyloid aggregation-inhibiting D-
peptide inhibitors on Aβ42 monomer and pentamer structures. The D-peptides, especially
the 12-residue D3 peptide, interact via electrostatic interactions with Aβ42’s Asp23, Glu22,
and Asp11 residues, to produce significant reduction in Aβ’s β-sheet content. While RD2,
a reshuffled form of D3 with a C-terminal penta-D-arginine sequence, presents similar
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binding pattern as D3 to Aβ42 monomer, it is slightly not as efficient at destroying Aβ42
monomer’s secondary structure; an effect which results from D3’s better ability to ad-
ditionaly interact with Aβ42 monomer’s hydrophobic residues. Truncated forms of RD2
including a penta-D-arginine peptide, bind strongly to Aβ42 monomer but failed to repro-
duce the amyloid-disrupting effect of RD2 and D3. Interestingly, with the Aβ42 pentamer,
RD2 produces a much greater β-sheet breaking effect than D3. This was observed to re-
sult from RD2’s greater ability to interact within Aβ42 pentamer’s fibril core. We suggest
this to be attributable to a difference in the Aβ oligomer specificity of the two D-peptides
and the possibility of deriving, via co-administration, a synergistic advantage from D3’s
effect on Aβ42 monomer and RD2’s on small Aβ42 oligomers. Furthermore, we performed
exhaustive point mutations of D3 and RD2’s sequences and assessed the resulting binding
free energies. The obtained results indicate that D3 is already highly optimised for Aβ42
monomer in agreement with the original phage display selection that identified D3 un-
der a set of solution conditions where monomeric Aβ42 was expected to be the dominant
species. On the other hand, substitutions with natural and non-natural amino acids with
single aromatic sidechains were observed to improve binding to Aβ42 pentamer.
While our use of representative hundreds of Aβ42-D-peptide systems successfully captured
important aspects of the interaction, it is still important to acknowledge that this number
represents only a very small fraction of the number of the interacting partners present in
a typical test tube. In particular, by selecting the top 100 complexes in each system our
results have become more narrowed to the set of systems analysed. The analyses would
doubtlessly have better modelled the ensemble averaged properties existing in vitro had
we included the entire 5000 GMIN-generated complexes. This, however, is currently be-
yond the computational resources available for the project. Also, the mutational analyses
employed only the binding configurations of the selected top D3-Aβ complexes. For in-
stance, the global energy minimum of each mutant may be expected to differ from that
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of the parent D-peptide-Aβ complex, and by ignoring this difference the mutation study
could not completely account for all energetic and configurational possibilities. In other
words, configurational entropy of the interacting peptide and inhibitors was not included.
On the other hand, fully sampling each of the ≈ 700 point mutations studied in this
work would require basin-hopping optimisation, binding energy calculation, and explicit
solvent MD simulations for about 3,500,000 different configurations!
Future work should consider the full optimisation of a number of point mutations se-
lected based, for instance, on the binding energies reported in this study. With this,
systematic chemical modifications may be employed for designing D-peptide-derived in-
hibitors with specificity for different Aβ oligomer size. In addition, the effect of varying
the Aβ-D-peptide stoichiometric ratio will also be conducted which will help to determine
the optimal number of D-peptides necessary to produce the largest structural effect on
Aβ. This study will require the profiling of Aβ aggregation process using atomistic MD
simulations of up to 20 for each of Aβ40 and Aβ42 peptides.
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7.1 List of abbreviations
Aβ Amyloid beta
AD Alzheimer’s disease
AFM Atomic force microscopy
APP Amyloid precursor peptide
BH Basin hopping
BBB Blood-brain barrier
CHC Central hydrophobic core
COM Centre of mass
CSF Cerebrospinal fluid
LTP Long-term potentiation
MD Molecular dynamics
NMR Nuclear magnetic resonance
QM Quantum mechanics
SRU Self-recognition unit
Tht Thioflavin T
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7.2 Amino acids codes
Ala (A) Alanine
Arg (R) Arginine
Asn (N) Asparagine
Asp (D) Aspartic acid
Cys (C) Cysteine
Gln (Q) Glutamine
Glu (E) Glutamic acid
Gly (G) Glycine
His (H) Histidine
Ile (I) Isoleucine
Leu (L) Leucine
Lys (K) Lysine
Met (M) Methionine
Phe (F) Phenylalanine
Pro (P) Proline
Ser (S) Serine
Thr (T) Threonine
Trp (W) Tryptophan
Tyr (Y) Glutamic acid
Val (V) Valine
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